WELCOME TO NIGMS COUNCIL. IT'S THE FIRST COUNCIL WE'LL TRY TO DO IN ONE DAY. THANKS FOR BEARING WITH US. WE HAVE A PACKED AGENDA. WE'LL TRY TO BE VERY EFFICIENT. WE'LL START WITH INTRODUCTIONS IF YOU COULD SAY WHO ARE AND WHERE YOU'RE FROM AND SOMETHING ABOUT WHAT YOU DO. SPEAK INTO THE MICROPHONES BECAUSE WE'RE VIDEOCASTING AND IT WILL BE ARCHIVED AS WELL AND THERE'S A FEW PEOPLE ON THE PHONE. IF THOSE ON THE PHONE COULD MUTE THAT WOULD BE GREAT SO WE DON'T GET FEEDBACK. ALSO, ONLY THREE PEOPLE CAN HAVE THEM ON AT THE SAME TIME SO AFTER YOU'VE USED IT TURN IT OFF. >> I'M THE EXECUTIVE SECRETARY OF COUNCIL. >> I'M FROM JOHNS HOPKINS A PROFESSOR IN CELL BIOLOGY AND THE ASSOCIATE DEAN FOR GRADUATE STUDENTS AT THE SCHOOL. >> I'M AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF COLORADO SCHOOL OF MEDICINE AND MY LAB WORKS ON TRANSLATION AND NNRA DECAY. >> I'M FROM PENN STATE. >> I'M FROM THE UNIVERSITY OF WASHINGTON IN SEATTLE. THE DEPARTMENT OF GENOME SCIENCES AND I STUDY BIOLOGICAL TUBE DEVELOPMENT. >> I'M SENIOR VICE PRESIDENT OF PRE CLINICAL DEVELOPMENT FOR MERCK AND WORK WITH TECHNICAL FUNCTIONS. >> GOOD MORNING, DEPARTMENT OF MEL -- MOLECULAR BIOPHYSICS FROM YALE AND I'M ALSO THE HEAD OF ONE OF YALE'S UNDERGRADUATE COLLEGES, BRANFORD COLLEGES. >> HELLO? >> I HAVE BEEN WORKING IN THE PHARMACEUTICAL INDUSTRY AT PFIZER MOST RECENTLY THE CEO OF AN IMMUNOVEN AND A CONSULTANT OUT OF MINNEAPOLIS. >> I'M FROM THE OFFICE OF RESEARCH DEVELOPMENT FOR THE U.S. DEPARTMENT OF VETERANS AFFAIRS. GOAL IS TO IMPROVE GENOMIC MEDICINE FOR VETERANS. >> I REPRESENT THE GIG ECONOMY FOR TODAY. I AM THE VICE PRESIDENT OF SCIENCE AND TECHNOLOGY AT THE UNIVERSITY CITY SCIENCE CENTER. IT'S THE LARGEST AND MOST ESTABLISHED URBAN RESEARCH CENTER IN THE COUNTRY IN WEST PHILADELPHIA. I PROVIDE GRANTS INTO REGIONAL UNIVERSITIES FOR COMMERCIALIZATION PROJECTS AND THEN ONCE THOSE PROJECTS COME OUT MAKING EARLY STAGE INVESTMENTS IN THOSE COMPANIES. >> I'M A PROFESSOR AT THE UNIVERSITY OF MARYLAND BALTIMORE COUNTY AN HHMI INVESTIGATOR AND P.I. ON AN IMSD GRANT FOR DIVERSIFYING THE Ph.D. PROGRAM. >> I'M A PROFESSOR OF EDUCATIONAL PSYCHOLOGY AT MICHIGAN STATE UNIVERSITY IN THE COLLEGE OF EDUCATION. I STUDY STUDENT MOTIVATION AND ENGAGEMENT IN SCIENCE WITH A SPECIFIC FOCUS ON PERSISTENCE. >> GOOD MORNING, I'M AN EMER TIS PROFESSOR FROM THE UNIVERSITY OF WYOMING. I'M A COMPARATIVE ENDOCRINOLOGIST BY TRAINING AND INTERESTED IN CAPACITY BUILDING ACROSS THE NATION. >> I'M ASSISTANT PROFESSOR OF PEDIATRICS AT VANDERBILT UNIVERSITY MEDICAL CENTER AND STUDY PRECISION MEDICINE AND PHARMACO GENOMICS WITH AN EMPHASIS ON HEALTH RECORDS. >> I'M FROM THE DEPARTMENT OF CHEMISTRY FROM UNIVERSITY CALIFORNIA IRVINE. MY LAB FOCUSES ON DEVELOPING METHODS TO MAKE MOLECULES OF IMPORTANCE IN THERAPEUTIC TREATMENT OF DISEASE. >> I'M A PROFESSOR IN COMPUTER SCIENCE DEPARTMENT AT THE UNIVERSITY OF DELAWARE AND WORK IN COMPUTATIONAL BIOLOGY AND WOK AT UNIVERSITY OF DELAWARE. MY RESEARCH ARE LANGUAGE PRCESSES ONTOLOGIES AND MACHINE LEARNING TO ASSIST WITH BIOMEDICINE. >> GOOD MORNING, EVERYONE. I'M A PROFESSOR AT THE ROCKEFELLER UNIVERSITY IN NEW YORK. MY LAB STUDIES THE CELL CYCLE, CELL DIVISION AND CYTOSKELETAL. >> GOOD MORNING. I'M DEPUTY DIRECTOR OF NIGMS. >> THANK YOU ALL VERY MUCH AND THANKS FOR YOUR SERVICE AND YOUR HELP HERE. FOR THOSE IN THE BACK, WE CAN'T BE STANDING IN HERE. THE FIRE MARSHAL WILL COME AND PUT US IN FIRE MARSHAL JAIL. THERE'S STILL SOME SEATS IN THE FRONT ROW HERE AND HERE. THERE'S ALSO AN OVERFLOW ROOM THAT'S VIDEOCASTING NEXT DOOR. SO THAT'S GOOD. THE TWO COUNCIL MEMBERS ON THE PHONE COULD YOU INTRODUCE YOURSELF AS WELL. >> CAN YOU HEAR ME? >> YES, WE CAN. >> I AM AT GEORGIA TECH AND CHAIR THE SCHOOL OF PUBLIC POLICY AND AN ECONOMIST BY TRAINING. >> GOOD MORNING. I'M PROFESSOR AND DIRECTOR OF THE CENTER FOR HEALTH EQUITY AT WAKE FOREST SCHOOL OF MEDICINE AND CONDUCT STUDIES IN ALZHEIMER'S DISEASE IN AFRICAN AMERICANS. >> WE HAVE ONE ORDER OF BUSINESS BEFORE WE START THE BUSY SCHEDULE THAT'S TO CONSIDER THE MINUTES FROM THE LAST MEETING. DOES ANYONE HAVE ANY CONCERNS OR AMENDMENTS TO THE MINUTES? IF NOT, I'M GOING TO CALL FOR A VOTE. DO I HAVE A MOTION TO APPROVE THE MINUTES? SECOND? ALL IN FAVOR. THANK YOU VERY MUCH. THOSE MINUTES ARE APPROVED. NOW, I WILL GIVE THE DIRECTOR'S REPORT AND WE'LL LAUNCH INTO THIS. >> THANK YOU ALL FOR COMING AND FOR ALL THE WORK YOU DID LEADING UP TO THIS EVENT. THIS AGAIN IS THE OPEN SESSION. THIS IS VIDEOCAST AND WILL BE AVAILABLE TO VIEW LATER FOR YOU OR YOUR FRIENDS. STARTING WITH SAD NEWS WITH HAVE RETIRING COUNCIL MEMBERS, GOLDIE, ON THE PHONE IS RETIRING FROM COUNCIL NOT THE REST OF THINGS, BUT FROM COUNCI AND BILL AND CARRIE ON THE PHONE AND SABIHAD AND LARRY OBERMAN JOINING US OR THE LAST COUNCIL SESSION THEY'LL BE ON COUNCIL. THERE'S BEAUTIFUL PLAQUES SIGNED BY THE SECRETARY HIMSELF TO HANG ON YOUR WALL. THANK YOU. YOU DESERVE A ROUND OF APPLAUSE. WE ALSO HAVE AD HOC PARTICIPANTS WHO INTRODUCED THEMSELVES BUT ONE HAS COME FROM MICHIGAN STATE UNIVERSITY AND CHERYL QUIN A HAND IN THE PHARMACEUTICAL INDUSTRY AND AS SHE SAID IS NOW AN INDEPENDENT CONSULTANT. WE'RE THANKFUL THEY'VE COME TO GIVE US THEIR INPUT. WE ALSO HAVE EARLY ROUND TWO EARLY CAREER INVESTIGATOR AD HOC PARTICIPANTS. WE BRING THEM TO SEE WHAT HAPPENS IN COUNCIL AND TELL OTHERS WHAT HAPPENS IN THE ADVISORY COUNCIL. WE LIKE TO DISSEMINATE INFORMATION TO THE COMMUNITY WHAT THE ROLE OF COUNCIL IS. OLIVIA AND SARAH, THANK YOU FOR JOINING US. SO OTHER NEW PEOPLE AND NEW HIRES TO THE INSTITUTE TO INTRODUCE. WE HAVE A NEW PROGRAM DIRECTOR IN RESEARCH CAPACITY BUILDING AND WE HAVE A HEALTH SCIENCE POLICY ANALYST. ANOTHER IS A SCIENTIFIC REVIEW OFFICER. ANDRE PHILLIPS IS A NEW PROGRAM DIRECTOR AND GMCDB AND WE WELCOME HIM AS WELL. IN ADDITION WE HAVE A NEW GRANTS MANAGEMENT SPECIALIST, CHRISTINA RINALDI AND SO WE ARE PLEASED TO HAVE RECRUITED THE TREMENDOUS GROUP OF PEOPLE. OF COURSE, WITH COMINGS THERE ARE GOES. WE HAVE SOME SAD GOINGS TO TELL YOU ABOUT. JIM DELRIDGE RETIRED RECENTLY. I KNOW IT'S IN THE CELL BIOLOGY COMMUNITY AND THERE'S WARM WISHES FOR JIM AS HE GOES TO THE NEXT PHASE OF HIS CAREER BUT HE WAS A TREMENDOUS ASSET. CHRIS WILLIS MANY KNEW AS A PROGRAM DIRECTOR TOOK A PROMOTION AND HAS MOVED TO THE NCI WHERE SHE'LL BE MANAGING PROGRAMS. A VERY BIG LOSS, WHICH IS NIH'S GAIN, I HAVE TO ANNOUNCE TODAY, SUSAN GREGRICK WAS APPOINTED LAST WEEK BY FRANCIS COLLINS TO BE THE NEW ASSOCIATE DIRECTOR FOR DATA SCIENCE AS WELL AS THE DIRECTOR OF THE DATA STRATEGY. IT'S A TREMENDOUS GAIN FOR NIH AND I THINK THEIR WHOLE RESEARCH COMMUNITY AS SUSAN IS THE PERSON TO LEAD THE EFFORTS AT NIH. SHE'S PROVEN THIS BECAUSE SHE'S DONE IT IN THE LAST YEAR IN AN AD HOC BASIS AND THIS ALLOWS HER TO HAVE ONE JOB INSTEAD OF TWO. WE'LL MISS YOU AND WE LOOK FORWARD TO WORKING WITH YOU CLOSELY IN THE NEW AND EXTREMELY IMPORTANT ENDEAVOR. THANKS FOR EVERYTHING YOU'VE DONE. >> THAT SAID WE HAVE TO MOVE ON AND SEARCH FOR REPLACE MANIES FOR THE YEAR REPLACEABLE. -- IRREPLACEABLE AND WILL LAUNCH A SEARCH FOR THE NEXT DIRECTOR OF THIS DIVISION. IN THE MEANTIME, JUDITH GREENBERG HAS GRACIOUSLY AGREED TO STEP IN AS THE ACTING DIRECTOR IN ADDITION OF BEING THE DEPUTY DIRECTOR OF THE INSTITUTE. SO IF YOU HAVE IDEAS FOR PEOPLE WHO WOULD BE GOOD FOR THIS POSITION, LET THEM KNOW THE SEARCH WILL BE STARTING SOON AND THEY SHOULD KEEP THEIR EYES OUT FOR POSTINGS ON THE FEEDBACK LOOP. THIS IS AN EXTREMELY IMPORTANT POSITION FOR NIGMS AND THE SCIENTIFIC COMMUNITY. WE HOPE TO ATTRACT SOMEONE EXCELLENT TO FILL SUSAN'S BIG SHOES. ANOTHER NIH WIDE DEPARTURE IS PAUL SEVING FROM THE NATIONAL EYE INSTITUTE. HE RETIRED THIS LAST JULY AND GONE TO U.K. -- UC DAVIS TO LAUNCH A CENTER. AND WE'LL HAVE AN ACTING DIRECTOR IN PLACE WHILE THEY CONDUCT A SEARCH. ANOTHER ONGOING SEARCH AT NIH. IN ADDITION TO THE COMINGS AND THE BIG HOLE AS THE BBC DIRECTOR WE HAVE A COUPLE MORE OPEENING -- OPENINGS. WE HAVE TWO PEOPLE RETIRING AFTER DOING MANY YEARS OF SERVICE AND WE NEED TO HIRE BEHIND IN THE BRANCH CHIEF POSITIONS. WE'RE LOOKING FOR A NEW BRANCH CHIEF IN BIOCHEMISTRY AND IN THE PHARMACOLOGIC SCIENCES BRANCH. IF YOU KNOW ANYONE WHO MIGHT BE GOOD FOR THESE POSITIONS, ENCOURAGE THEM TOTHEM TO APPLY IF YOU HAVE QUESTIONS WE'D BE HAPPY TO HELP PEOPLE APPLY FOR A FEDERAL JOB IN THIS WAY. AN EXCITING THING HAPPENED LAST WEEK IN THE ROOM WHICH WAS A RESEARCH ORGANISM WORKSHOP DORIT ZUK ORGANIZED ON CHOOSING A RESEARCH ORGANISM BEST FOR THE STUDY YOU'RE CONDUCTING. ALEJANDRO SANCHEZ ALVARADO GAVE AN INSPIRING KEY NOTE ADDRESS WHICH I ENCOURAGE YOU TO WATCH AND GO TO THE NIH VIDEOCAST SITE SHOWN THERE AND WATCH THE ARCHIVE OF THE ENTIRE DAY BUT IN PARTICULAR I'D POINT YOU TO HIS TALK IF YOU ONLY HAVE TIME FOR ONE THING. THOUGH THE ENTIRE DAY WAS EXCELLENT. I THINK IT WAS AN EXCITING EVENT. WE LEARNED A LOT. . HOPEFULLY HELP US PUSH FORWARD IN GETTING THE COMMUNITY TO THINK MORE ABOUT MOVING INTO A MORE DIVERSE ARRAY OF ORGANISMS IN STUDIES BECAUSE WHAT WAS CLEAR FROM ALL THE TALKS WE HEARD IS THAT THERE'S A LOT OF BIOLOGY OUT THERE WAITING TO BE DISCOVERED AND WE LEARNED A TINY FRACTION OF WHAT EXISTS IN THE WORLD. THE UPCOMING ELECTION AND THIS IS A NAME LECTURE NIGMS HOSTS. THIS YEAR'S SPEAKER IS CHRISTINA SMOLKE FROM YALE UNIVERSITY TALKING ABOUT SCALEABLE PLATFORMS FOR RNA SENSORS AND CONTROLLERS. I THINK IT WILL BE AN INTERESTING TALK. OCTOBER 23, 3:00 TO 4:00 P.M. AT THE MASUR ADD -- AUDITORIUM AND FREE AND YOU CAN WATCH IT REMOTELY OR LIVE AND IT WILL BE ARCHIVED IN THE VIDEOCAST SITE. I THINK IT WILL BE A GREAT TALK. I WANT TO UPDATE A LITTLE BIT ON SOMETHING WE TALKED ABOUT LAST TIME WHICH IS THE NEW COLLABORATION WITH SCHOLASTIC INCORPORATED THE MATH -- PATHWAYS MAGAZINE. PROBABLY ALL ARE FAMILIAR WITH SCHOLASTIC THAT HAS DEEP REACH INTO THE SCHOOLS IN THE COUNTRY AND WE STARTED THIS VENTURE THROUGH THE OFFICE OF COMMUNICATION AND STEPHANIE OLDER TO PUT OUT A MAGAZINE TARGETED FOR BASIC BIOMEDICAL RESEARCH AND TRYING TO GET KIDS INTERESTED IN THOSE CAREERS AND THAT AREA. THE FIRST ISSUE LAUNCHED LAST TIME. IT WAS ABOUT CAREERS IN BASIC BIOMEDICAL RESEARCH. IT REACHED 2.5 MILLION MIDDLE SCHOOL CHILDREN AND 19,000 TEACHERS IN ALL 50 STATES. THERE'S THE MAGAZINE WHICH WE GAVE YOU A COPY OF LAST TIME AND IN ADDITION ONLINE THERE'S OTHER RESOURCES INCLUDING LESSON PLANS FOR TEACHERS THAT ARE ACTUALLY MATCHED TO THE CURRICULAR STANDARDS TO USE THOSE EFFECTIVELY IN THEIR TEACHING AND A NUMBER OF ONLINE ACTIVITIES AND VIDEOS WORTH WATCHING IF YOU HAVEN'T SEEN THEM YET. THERE'S THE WEBSITE YOU CAN SEE INCLUDING THE MAGAZINE. I URGE YOU IF YOU HAVEN'T TO LOOK AT THAT. SCHOLASTIC DID SOME SURVEYING OF THE PEOPLE WHO GOT IT AND FROM THE TEACHER SURVEY, 88% SAID THEY PLANNED TO USE THE PATHWAYS MATERIAL. 79% SAID THEY FOUND THE MATERIALS VERY USEFUL AND 97% SAID THEY WANTED TO SEE MORE OF THE SAME KIND OF THINGS. BECAUSE OF THAT ENDORSEMENT WE HAVE A SECOND ISSUE. IT'S OFF THE PRESS YESTERDAY AND ABOUT REGENERATION AND REGENERATIVE BIOLOGY. VERY COOL. IT SHOWS THINGS LIKE MEXICAN SALAMANDERS THAT CAN DO AMAZING REGENERATION AND HIGHLIGHTS OTHER RESEARCHERS AND WE'LL GIVE YOU A COPY BEFORE YOU LEAVE FOR THOSE ON KRRNS. WE'RE EXCITED ABOUT THE CONTINUING CAROLINA RATION AND -- CONTINUING COLLABORATION AND THE OUTREACH POTENTIAL IT HAS. I WANT TO TALK ABOUT THINGS GOING ON INTERNALLY, ADMINISTRATIVELY BY OUR OFFICE OF PROGRAM ANALYSIS AND EVALUATION. RICHARD ARRAGON'S GROUP THAT TALKED ABOUT ANALYTICS AND EVALUATION PROJECTS WE'VE DONE. THIS GROUP PUBLISHED NOT ONE TWO PAPERS THIS YEAR AND BOTH LOOKED AT THE NIGMS SMALL BUSINESS PORTFOLIOS. THE FIRST LOOKED AT GEOGRAPHIC DISTRIBUTION OF OUR GRANTS AND LOOKED FOR RELATIONSHIPS TO THE OUTCOMES OF THOSE INVESTMENTS WHERE THE GEOGRAPHIC DISTRIBUTION. PROBABLY THE BIGGEST TAKE-HOME MESSAGE IS CLOSE PROXIMITY BETWEEN THE SMALL BUSINESS AND A MAJOR RESEARCH UNIVERSITY HAD A SIGNIFICANT POSITIVE CORRELATION FOR THE OUTCOMES FOR THAT SMALL BUSINESS. THAT'S SOMETHING ACTIONABLE WE CAN THINK ABOUT IN MAKING FUNDING DECISIONS AN RESEARCHERS WHO ARE GOING TO SAID UP COMPANIES CAN USE WHEN THEY THINK WHERE TO LOCATE THEIR COMPANY. SECOND IS LINKED NIGMS PATENT DATA AND LOOK AT INNOVATION, COMMERCIALIZATION AND THE SURVIVAL OF STTR COMPANIES. WE MEAN COMPANIES NOT THE P.I.s. HOPEFULLY THEY'RE NOT RELATED TO ONE ANOTHER. WE CAN MAKE THE LINKAGES TO VARIOUS OTHER KINDS OF OUTCOMES DATABASES LIKE THE PATENT OFFICE OR BUSINESS INTELLIGENCE RATHER THAN USING SURVEY INSTRUMENTS WHICH HAS BEEN DONE IN THE PAST. WE FOUND THE PROGRAMS EXCEEDED AND OUT PERFORMED BASELINE EXPECTATIONS ACROSS ALL THE DIMENSIONS WE LOOKED AT. THE PROGRAM SEEMS TO BE PERFORMING WELL AND THE NEXT STEP IS FIND ACTIONABLE WAYS TO IMPROVE THE PERFORMANCE FURTHER. THAT'S THE NEXT CHALLENGE TO TRY IN THIS LINE OF RESEARCH. ANOTHER THING AND CATHY MENTIONED HER RESEARCH ON MACHINE LEARNING AND NATURAL LANGUAGE PROCESSING SO THIS IS RELEVANT TO THAT, WORK LED BY NATHAN MOORE WITH DORIT ZUK AND JOSƒ LOPEZ FROM OUR INFORMATION RESEARCH RESOURCES BRANCH. TO FIND MORE EFFICIENT WAYS FOR US TO DISTRIBUTE APPLICATIONS WHEN THEY COME IN TO THE APPROPRIATE PROGRAM DIRECTORS, OFFICERS. THE WAY IT'S HISTORICALLY BEEN DONE IS BY HUMANS AND THEY DECIDE WHERE IT SHOULD GO AND THAT'S A PROCESS THAT CAN TAKE A DAY OR TWO TO FIND THE RIGHT HOME TO TWO TO THREE WEEKS TO FIND THE RIGHT HOME. SO NATHAN DEVELOPED A PROGRAM WHERE WE USED NATURAL LANGUAGE PROCESSING AND MACHINE LEARNING TO LEARN WHERE THE APPLICATIONS SHOULD GO BASED ON THE TEXT AND CONTENT OF APPLICATIONS AND ASSIGNED THEM FIRST TO, IF YOU LOOK AT THE TRIANGLE TO DECIDE IF THE APPLICATION'S IN THE NIGMS MISSIONARY AND IF NOT IT ASSIGNS IT TO A DIVISION AND BRANCH AND A CERTAIN PROGRAM OFFICER WITHIN THAT BRANCH. WHAT HE WE FOUND IS FIRST THIS ALLO ALLOWS SUBSTANTIAL TIME SAVINGS. IT'S SOMETHING ON THE ORDER OF 20,000 PERSON HOURS ARE SAVED A YEAR WHICH FREES UP OUR PROGRAM OFFICERS AND OTHERS TO FOCUS ON HIGHER VALUE AND INTELLECT SORTS OF WORK. IT ALLOWS FOR OBJECTIVE AND STANDARDIZATION. YOU CAN IMAGINE THIS COULD BE USED FOR REFERRING APPLICATIONS TO STUDY SECTIONS AS WELL. IT RETAINS INFORMATIONAL KNOWLEDGE UNLIKE PEOPLE WHO MOVE ON OCCASIONALLY AND IF THEY LEAVE WE LOSE THEIR INSTITUTIONAL KNOWLEDGE. THIS IS NOW IN THE PROGRAM AND IF A PERSON LEAVES WE DON'T -- CELESTE. >> DOES THE PROGRAM WORK JUST OFF THE PROJECT OR -- >> THE WHOLE THING I BELIEVE. WHAT'S MORE IMPRESSIVE IS IT'S 92% ACCURATE IN GETTING IT TO THE RIGHT SCIENTIFIC DIVISION AND 84% IN TERMS OF GETTING IT TO THE RIGHT OFFICER WHICH IS THE SAME ACCURACY OF A HUMAN DOING IT SO THE PROGRAM MATCHES HUMANS. THIS IS BEEN RECEIVING TENSION THROUGH NIH WE'RE WORKING TO INCORPORATE THIS INTO THE ENTERPRISE WIDE SYSTEMS TO ALLOW ALL INSTITUTES AND CENTER TO USE IT AND THE WAY WAS HIS FEATURED ON THE DATA STRATEGY WEBSITE AS AN IMPORTANT ADVANCE. LET'S TALK ABOUT NOVO GAS, THE FIRST BEING MEAL -- HELIUM. I DON'T KNOW IF YOU KNOW THERE'S A WORLDWIDE HELIUM SHORTAGE AND IT'S NOT JUST A PROBLEM FOR BIRTHDAY PARTIES BUT ALSO FOR RESEARCH AND IN FACT FOR MEDICAL CARE AS WELL BECAUSE MRI INSTRUMENTS REQUIRE THE USE OF LIQUID HELIUM. SO WHAT'S THE PROBLEM? IT'S A BYPRODUCT OF A NATURAL GAS AND A NON-RENEWABLE RESOURCE BECAUSE WHEN IT'S RELEASED YOU TAKE YOUR BALLOON FROM THE PARTY AND INHALE IT AND TALK IN A HIGH VOICE FOR A MINUTE AND IT DOESN'T GO INTO A HELIUM CYCLE, IT FLOATS INTO THE AT MOSS FOREAND INTO SPACE. I'M -- ATMOSPHERE AND INTO SPACE SO IT'S GONE FOREVER. INDUSTRY DEMAND IS INCREASING. SO IF WE'RE MAKING ELECTRONICS AND FOR MEDICAL PURPOSE, CRYOGENS FOR MRIs AND OTHER MEDIC MEDIC MEDICAL EQUIPMENT IS AVAILABLE AND IT'S DECREASING BECAUSE OF WORLDWIDE SUPPLY PROBLEMS DUE TO GEOPOLITICAL ISSUES AND U.S. LAW REQUIRES THE HELIUM RESERVE HAS TO CEASE OPERATION BY 2021 AND IT WAS ARTIFICIALLY LOWERING PRICES OF HELIUM RELATIVE TO THE MARKET RATE. SO THAT IS GOING TO LEAD AND IS LEADING TO AN INCREASE IN PRICE AND SERIOUS INSTABILITY IN WHEN YOU CAN GET HELIUM WHICH IS A PROBLEM IF YOU HAVE A SUPER CONDUCTING MAGNET ON YOUR MMR AND DON'T KNOW WHEN YOU'RE NEXT HELI HELIUM SUPPLY WILL COME. THERE WAS A REPORT BY THE MATERIALS RESEARCH SOCIETY AND AMERICAN CHEMICALS SOCIETY IN 2016 ON THE ISSUE. THESE ARE A COUPLE QUOTATIONS FROM THAT REPORT. ONE GROUP REPORTED THE HELIUM COSTS HAVE INCREASED BY 250%. ANOTHER SAID HE HAD TO SKIP HIS SUMMER SALARY FOR HELIUM. THAT'S DEDICATION TO SCIENCE BUT I DON'T IT'S WHAT WE WANT. THIS SAY PROBLEM MICHELLE BROUGHT TO OUR ATTENTION AND WENT FROM IDENTIFYING THE PROBLEM TO THE FEEDBACK LOOP MAY HAVE BEEN TWO WEEKS, MAYBE 10 DAYS A CALL SAYING WE WERE INTERESTED AS PART OF OUR EQUIPMENT SETTLEMENT PROGRAM, FUNDING INSTITUTION TO PURCHASE OR UPGRADE OR PAIR HELIUM ROW CYCLING CENTERS. IT WAS A TIGHT TIME LINE, DESPITE THAT WE GOT A LOT OF APPLICATIONS. IN END, WE WERE ABLE TO FUND $5.5 MILLION WORTH AND FIVE NEW COMPLETELY NEW SYSTEMS FOR PLACES THAT WERE NOT RECYCLING HELIUM PREVIOUSLY AND HAD SYSTEMS TO MAKE THEM CONTINUE TO FUNCTION. I THINK THE PRIZE WENT TO BERKELEY WHICH HAS HAD A HELIUM RECYCLING PROGRAM FOR 44 YEARS. THAT IS PRETTY PRESCIENT SO KUDOS TO THEM FOR REALIZING IT WOULD BE A PROBLEM. EACH WILL HELP RESEARCHERS FUNDED BY OTHER NIH INSTITUTES, PROBABLY THE NSF, FEDERAL AGENCIES, ETCETERA. IT'S 90% EFFICIENT AND MICHELLE ESTIMATES THE 26 SYSTEMS ARE GOING TO SAVE AN ARGUE OF MORE THAN 100,000 LITERS OF LIQUID HELIUM A YEAR WHICH AT THE CURRENT MARKET RATE IS $1.5 MILLION. IN FOUR YEARS THIS INVESTMENT IS GOING TO PAY ITSELF BACK NOR RESEARCH SYSTEM. I THINK THAT'S A TREMENDOUS INVESTMENT AND USE OF RESEARCH SUPPLEMENTS. WANTED TO MAKE YOU AWARE OF ONE OF THE IMPORTANT THINGS WITH THE RESEARCH SUPPLEMENTS. >> ARE PLANS FOR ANOTHER ROUND OF THOSE SUPPLEMENTS? >> WE HOPE SO. IT DEPENDS ON BUDGET AND MONEY WE AREN'T ALREADY COMMITTED TO BUT WE'VE BEEN AGGRESSIVE. THIS SAY CLEAR INVESTMENT WHERE IT PAYS ITSELF BACK. AND THE MURA FUNDING ANNOUNCEMENT WAS REISSUED. THERE WAS SLOWING IN TRYING TO GET IT THROUGH THE SYSTEM BUT IT'S OUT NOW. IT'S SIMILAR TO THE PREVIOUS ONE IN PHILOSOPHY AND GUIDANCE. THIS IS THE FIRST MIRA FOA THAT ALLOWS FOR RENEWALS. THE FIRST PEOPLE ARE ABOUT TO GET TO THE POINT WHERE IT'S NOT FOR THEM TO THINK ABOUT APPLYING AND IT WILL ALLOW FOR RENEWABLES TO HAPPEN AND IT DEPENDS ON HOW MANY DON'T APPLY FOR RENEWALS BUT OUR INTENT AS PART OF THE STABILITY INTO THE PROGRAM IS TO MAKE THE RENEWAL RATE HIGH. AND YOU CAN HAVE A SECOND ATTEMPT AT RENEWING. IT WON'T BE JUST A ONE-SHOT THING. IT ALSO GIVES CONSIDERABLY EXPANDED TIME FOR PEOPLE TRYING TO GET A NEW MIRA FROM AN RO1 TOE APPLY FOR IT -- TO APPLY FOR IT AS WELL. ONE INNOVATION WHICH GOES TO ERICA BROWN IS THAT THIS WILL NOT REQUIRE A DETAILED BUDGET. ERICA FOUND WAY TO DO THIS AND THERE'S SAVINGS FOR THE APPLICANT AND ALSO BE A REDUCTION IN BURDEN FOR REVIEWERS IN WELL WE ALSO EXPANDED THE KINDS OF AWARDS HE WILL VIB. TP1s AND TRANSFORMATIVE AWARDS FROM THE COMMON FUND IF THEY WERE MANAGED FROM NAGMSC ARE ELGIBLE TO CONVERT TO MIRAs. AND THOSE COMING IN FOR THEIR FIRST RENEWAL WHETHER IT WAS MIRA OR RO1 WILL BE CLUSTERED IN REVIEW AND COMPARED TO ONE ANOTHER. THE REVIEW OF ALL THE MIRAs WILL BE HANDLED BY CSR. THERE'LL BE TWO ESTABLISHED INVESTIGATOR ROUND AND ONE EARLY STAGE INVESTIGATORS AND THEY'LL BE IN THEIR OWN PANELS AGAIN, PEOPLE COMING IN FOR THEIR FIRST RENEWALS WILL BE CLUSTERED IN THE PANELS. THIS IS THE NUMBER OF EARLY STAGE INVESTIGATORS FUNDED IN BLUE. THE BOTTOM BARS ARE THOSE FUNDED BY RO16 -- RO1s AND THE GREEN ARE THE OTHER. WE FUNDED ABOUT A HUNDRED EARLY STAGE INVESTIGATORS. 2016 IS THE FIRST TIME WE FUNDED EARLY STAGE INVESTIGATOR MIRAs AND WE JUMPED IN HOW MANY WE FUNDED 150 OR SO. 44% OF WHICH CAME IN AS MIRAs. THEN WE JUMPED TO WHO WE FUNDED THE MOST OF ANY INSTITUTE OR CENTER. A NUMBER CAME IN THROUGH THE MIA PROGRAM. ONLY 60% IN 2018 AND CLOSE TO 75% WILL HAVE BEEN THROUGH MIRA THIS FISCAL YEAR. THAT IS AN UNDERESTIMATE OF HOW MANY CSI WE'LL FUNDAL WE'LL BE CLOSER TO 10 OR MORE THAN THAT. >> HAVE THE NUMBER GONE UP OR ARE YOU FUNDING MORE E.S.I. INVESTIGATORS? >> BOTH. AS SOON AS MIRA CAME ONLINE WE SAW AN INCREASE IN APPLICATION TO NAGMSC BUT WE'RE ALSO FUNDING MORE IT'S A STRATEGIC DECISION ON THE PART OF THE INSTITUTE TO PRIORITIZE EARLY STAGE INVESTIGATORS. WE HOPE IT CONTINUES BUT IT SEEMS LIKE PEOPLE ARE VOTING WITH THEIR FEET AND COMING INTO THE PROGRAM. I WANT TO END WITH NEW PROGRAMS WE'RE JUST LAUNCHING AND YOU, COUNCIL, WERE INVOLVED IN ADD ADVISING US ON THE MOW -- MOSAIC PROGRAM. THE GOAL IS TO HAVE POST-BACS FROM DIFFERENT BACKGROUNDS AT RESEARCH INTENSIVE INSTITUTIONS. IT WAS A SIGNIFICANT LOSS POINT FOR THE RESEARCH ENTERPRISE. WE MADE STRIDES WE DECIDED WE HAD TO DO SOMETHING TO BRIDGE THE GAP AND HENCE THE MOSAIC PERHAP. THE FIRST PART ARE UE5 AWARDS. SO THESE ARE THE COOPERATE AGREEMENT EQUIVALENTS OF R25 RESEARCH EDUCATION GRANTS. THESE WILL GO TO PROFESIONAL SOCIETIES OR RELATED ORANIZATIONS WHERE WE'LL PROBABLY FUND THREE IN THE FIRST ITERATION AND ONE UE5 AT PROFESSIONAL SOCIETY A AND THEN B AND STAFFED CLEVERLY SO IT DIDN'T HAVE TO BE A SINGLE PROFESSIONAL SOCIETY BUT MULTIPLE SOCIETIES COULD BAN TOGETHER TO FORM A SINGLE NUKE NUCLEATING ORGANIZATION. THEY'LL FORM NUCLEATING CENTERS AROUND WHICH FELLOWS WILL BE ORGANIZED, MENTORED AND GIVEN OTHER CAREER ADVANCEMENT OPPORTUNITIES. SO THAT'S THE SECOND PART IS THE COHORTS OF DIVERSITY FOCUS K99, ROOs THROUGH A SECOND FOA PROBABLY 15 OR SO PER YEAR, ROUGHLY, DEPENDING ON THE ISSUES AND THE RECIPIENTS WILL BE BROKEN INTO COHORTS DEPENDING ON SCIENTIFIC INTEREST AND MATCHED WITH THE NUCLEATING CENTERS. THESE GUYS ARE NOW POST-DOCS. THEY'LL GET SECOND MENTORING AND FUND ANOTHER COHORT AND THEY'RE BOTH POST DOCKS. THE THIRD YEAR WILL FUND ANOTHER ONE AND IF EVERYTHING GOES RIGHT THE COHORT WILL HAVE TRANSITION WITH HELP OF MENTORING FROM THE UE5s AND OTHERS TO IN DEPEND -- INDEPENDENT PHASE GEDDING FUNDING AS INDEPENDENT RESEARCHERS AND NOW COHORT TWO IS TRANSITIONED TO FACULTY. THE UE5s WILL PROVIDE A VARIETY OF OTHER CAREER DEVELOPMENT SERVICES, TEAM BUILDING, PROFESSIONAL SKILLS DEVELOPMENT AND COURSES, ETCETERA. ADDITIONAL MENTORING, PROFESSIONAL NETWORK DEVELOPMENT, CAREER DEVELOPMENT AND WORKING WITH NIH AND PART OF WHY IT'S A COOPERATIVE AGREEMENT TO ENSURE INSTITUTIONAL RESPONSIBILITY TO THE FELLOWS. THEY CAN GO FROM WHEREVER THEY WANT TO GET JOBS AND WE WANT TO MAKE SURE THE INSTITUTIONS THAT HAVE THE FELLOWS OR JUNIOR FACULTY ARE LIVING UP TO THEIR SIDE OF THE BARGAIN IN TERMS OF SUPPORTING THEM AND DOING THINGS THEY SAID THEY'D DO. THAT'S WHERE HAVING PROFESSIONAL SOCIETIES AND HAVE NIH WORK IN PARTNERSHIP WITH THEM THEY BE EFFECTIVE. ON THE K99R00 IT PROVIDING FUNDING AS POST-DOCS AND FUNDING WHEN THEY'RE JUNIOR FACULTY AND PROVIDE ADDITIONAL MENTORING FROM THEIR K99 FELLOWS INCLUDING THE PROGRAM OFFICERS. THUN -- ONE THING I LIKE IS THEY HELP THE FELLOWS WHEN THEY'RE NEGOTIATING FOR START-UP PACKAGES AND THINGS LIKE THAT. THERE'S BEEN CASES WHERE INSTITUTIONS WERE PLAYING FAST AND LOOSE AND THE PROGRAM OFFICERS WERE ABLE TO REDIRECT THINGS TO BE MORE EQUITABLE AND FAIR. I THINK THAT'S IMPORTANT. WE LOOK TO NEAR PEER MENTORING. HAVE YOU SOME JUNIOR FACULTY, SOME POST-DOC. WE HOPE THEY'LL BE IN THE SYSTEM TO BE MENTORING ONE ANOTHER. WE THANK IS POWERFUL AND THROUGH THE K99R00 IT GIVES FELLOWS ADDITIONAL INDEPENDENCE TO EXPLORE RESEARCH THEY'RE INTERESTED IN AND NOT BE SO TIED TO MENTOR AND HIS OR HER R01s. WE'RE HOPING IT WILL BE EFFECTIVE. IT'S AN EXPERIMENT. OTHER INSTITUTES ARE INTERESTED IN JOINING IN. THE FOA WAS WRITTEN SUCH OTHER INSTITUTES CAN SLIDE IN AND FUND THEIR OWN UE5s AND COHORT OF FELLOWS. WE HOPE IT WILL BE A MODEL TO TAKE OFF ACROSS NIH. THE LAST THING I WANT TO MENTION IS THE WORK ON NATIONAL AND REGIONAL TECHNOLOGY RESOURCES. THERE WAS CONCERN THERE WERE TOO MANY FUNDING MECHANISMS AND WAYS THEY WERE BEING FUNDED AND WEREN'T BEING COMPARED TO EACH OTHER OR NECESSARILY HELD TO THE SAME STANDARDS. THAT LED US TO DEVELOP WITH YOUR INPUT WITH AN FOA AND THEY'LL BE COMPARED AND MAKE SURE THEY'RE ALL FOCUSSING ON UTILITY EFFICIENCY OF OPERATIONS AS THEY SHOULD BE. WE THEN USED THAT MODEL FOR WHAT THE LINES DO BORE THE COMMUNITY, ECONOMIES OF SCALE, UTILITY AND THE IMMENSELY INCREASED ACCESS TO THAT KIND OF TECHNOLOGY. WHEN WE WORKED ON AND NOW MANAGED THE COMMON FUND CRYO-EM CENTERS INITIATIVE. THERE'S NOW THREE CENTERS FUNDED ACROSS THE COUNTRY. ONE IN NEW YORK, AT THE NEW YORK STRUCTURE BIOLOGY CENTER, ONE AT OREGON HEALTH SCIENCES IN COLLABORATION WITH THE PACIFIC NORTHWEST NATIONAL CENTER AND ONE AT STANFORD, SLACK. THOSE ARE ONLINE, UP AND RUNNING. THE FIRST HIGH VOLTAGE EMs ARE BEING DELIVERED AS WE SPEAK OR ACTUALLY ON SITE. WE ACTUALLY FUNDED THROUGH EQUIPMENT SUPPLEMENTS AN ADDITIONAL HIGH VOLTAGE MICROSCOPE FOR EACH SITE AND THEY'LL NOW HAVE FIVE INSTEAD OF FOUR. I THINK IT WILL BE POWERFUL BUT BUILT ON THE MODEL. WE RECENTLY RELEASED TWO FOAs TO EXPAND THE CENTERS TO INCLUDE NEW CENTERS FOR CRYOELECTRONIC TAMOGRAPHY AND YOU GET HIGH RESOLUTION STRUCTURES AND CRYO-FM TAMOGRAPHY LOOK AT CELLS AND IT'S NOT AS HIGH RESOLUTION YET BUT THERE'S TREMENDOUS POTENTIAL. IMAGINE YOU CAN GET NEAR ATOMIC STRUCTURES OF MOLECULES DOING THEIR BUSINESS INSIDE OF A CELL. THE KINDS OF THINGS YOU CAN LOOK AT IS MIND BLOWING. THIS ALLOWS RESEARCHERS ACCESS TO THE TECHNOLOGY BECAUSE IT'S NOT WIDELY AVAILABLE AND A PLACE WHERE PEOPLE CAN WORK ON ADDITIONAL METHODOLOGY AND PUSHING TECHNOLOGY FORWARD. THEY CLOSE IN NOVEMBER. THERE'S STILL TIME. IF YOU KNOW PEOPLE WHO ARE DOING CRYO-E.T. AND MAY BE GOOD FOR ONE OF THESE CENTERS, MAKE SURE THEY KNOW ABOUT THIS. IT'S A WIN-WIN. THOUGH YOU'RE RUNNING A CENTER PEOPLE CAN BENEFIT FROM THESE THINGS. WE EXPANDED THE MODEL TO COVER ADDITIONAL TECHNOLOGIES. RECENTLY WE SUPPORTED NATIONAL AND REGIONAL RESOURCES IN VARIOUS TECHNOLOGY AREAS. THE COMMUNITY CAN PUT IN AN APPLICATION TO GET RESEARCH FOR THAT TECHNOLOGY. SOME THINGS NEED TO BE BORNE IN MIND. THIS TECHNOLOGY AND RESOURCE WOULD NEED TO HAVE A LARGE NATIONAL OR AT LEAST REGIONAL. WE MEAN MULTISTATE OOUS COMMUNITY. -- USER COMMUNITY AND THE SYNCERTRONS AND WE'RE TALKING HUNDREDS OF USERS. IF THIS SOMETHING MOST INSTITUTIONS DON'T HAVE ACCESS TO, THEN NOW WE'RE TALKING. WE WANT TO SEE IT CREATE ECONOMIES OF SCALE. THAT'S IMPORTANT. THE SYNCERTRONS AND CENTERS CREATE ECONOMIES OF SCALE BECAUSE NOT EVERY INSTITUTION HAS TO BUY ITS OWN HIGH-END PIECE OF EQUIPMENT OR HAVE THE EXPERT STAFF TO RUN IT. IT'S ALL IN ONE PLACE AND CAN BE MUCH MORE EFFICIENTLY RUN. FINALLY, THE CENTERS NEED TO FOCUS ON USER SERVICE AND EFFICIENCY OF OPERATION. IF SOMEONE WANTS TO DO THEIR OWN RESEARCH AND TECHNOLOGY, THIS IS NOT WHAT YOU WANT. YOU WANT TO TALK ABOUT ONE OF OUR DEVELOPMENT TECHNOLOGIES RO1s OR P41 CENTER. THIS IS FOR USER SERVICE AND WE'LL LOOK AT HOW MANY USERS GET ACCESS AND HOW GOOD THE ACCESS IS AND HOW EFFICIENT TIS -- IT IS TO OPERATE. WITH THAT I'M HAPPY TO TAKE QUESTIONS? HOW ARE WE FOR TIME? WE'RE GOOD. >> WE HAVE AN IDEA WHAT THE INSTITUTIONS ARE SPANNING? >> ANECDOTALLY ONE THING PLEASING TO SEE IT APPEARS THERE'S MORE DIVERSITY OF INSTITUTIONS PEOPLE ARE COMING FROM. >> YOU'RE AT AN R15 INSTITUTION ARE YOU ENCOURAGED TO WRITE ONE OF THESE OR BETTER TO WRITE AN R15. >> IT'S A GOOD QUESTION AND DEPENDS ON AN INDIVIDUAL'S SITUATION. AN R15 IS GOOD IF YOU'RE DOING UNDERGRADUATE RESEARCH. WE FUND A LOT OF THEM MORE THAN ANY OTHER INSTITUTE. BUT IF ANYONE HAS A PROGRAM THAT FITS THE MIRA THAT MAY BE A WAY TO GO. >> FOR THE MOSAIC PROGRAM IS FOR MINORITIES OR FOR WOMEN WHO ALSO DROP OUT AT THE SAME TRANSITION? >> IT'S DIVERSITY IN GENERAL. IF A GROUP IS UNDER REPRESENTED AT THE FACULTY LEVEL THAT'S A GROUP THAT WOULD BUILD DIVERSITY ENTERPRISE. UNDER REPRESENTED MINORITIES, WOMEN, YES. WE'RE LOOKING AT SOCIOECONOMIC DISADVANTAGED GROWING UP, FIRST GENERATION COLLEGE. THESE KINDS OF THINGS. WE'RE LOOKING TO BUILD THE DIVERSITY ENTERPRISE. ANYTHING UNDER REPRESENTED WHATEVER THE DIMENSION I THINK IT FAIR GAME. >> ON THE HELIUM RECYCLING WERE ANY APPLICATIONS SUBMITTED OR FUNDED INTO THE IDEA STATE GROUP? IT SEEMS LIKE IF WE FUND ONE LESS COBRE WE CAN HELP PEOPLE IN PUERTO RICO WITH THOSE. >> SHE CAN GIVE YOU THE NUMBERS. WE LOOK AT THAT DARRIN TO REACH AS MANY STATES AS POSSIBLE. SHE THINKS THERE'S A SUCCESS RATE OF 100% FROM IDEA STATES. >> IS THAT ONE OUT OF ONE? >> I WAS STRUCK ON THE MOSAIC PROGRAM HOW A LOT OF THE GOES LOOK FOR GRANTS. THEY'RE MENTORING AND ALL SORTS OF THINGS. I'D BE ENCOURAGED TO THINK ABOUT WAYS YOU COULD TIE COBRA TO THE OUTPUT OF K99s, ROOs BECAUSE INSTITUTIONS LIKE MINE HIRE FEW K99s. WE'D LIKE MORE BECAUSE IT'S A NATURAL NE MECHANISM FOR RESEARCH EXPERTISE. >> YOU'RE RIGHT ON BOTH COUNTS, AS USUAL. THE COBREs WERE PART OF WHAT WE WERE THINKING AND USING THEM AS PART OF THE PIPELINE IS AGREAT IDEA AND ENCOURAGE HOW BEST TO CAPITALIZE ON THIS. MIKE. >> HAVE YOU MIRE RECIPIENTS COMING UP FOR RENEWALS SOON IT WOULD BE INTERESTING TO LOOK AT THE TOOLS YOU LOOKED AT FOR PRODUCTIVITY RO1 RECIPIENTS. >> THAT'S PART OF THE EVALUATION PLAN TO COMPARE. WE HAVE NATURAL CONTROL GROUPS. RO1 VERSUS MIRA. LARRY. >> WAY -- I JUST WANTED TO SECOND THE HELIUM RECYCLING AND I HOPE THERE'S A SECOND CALL FOR THAT. >> WE HEAR YOU. WE'LL DO EVERYTHING WE CAN. OLIVIA. >> FOR THE MIRAs DO YOU TRACK SUCCESS RATES FOR MINORITIES AND WOMEN BUT HOW MUCH MONEY RECIPIENTS RECEIVE SO MAKE SURE THEY'RE ALSO EQUITABLE. >> THE ISSUE FOR THE ESTABLISHED INVESTIGATORS IS THE NUMBERS ARE NOT OF WOMEN BUT OF UNDERREPRESENTED MINORITY ARE VERY LOW. THE STATISTICS IS DIFFICULT TO DO. AND THOSE POOLS ARE SET BECAUSE WHOEVER WAS AN ESTABLISHED INVESTIGATOR. THE EARLY STAGE WE LOOKED AT A LOT, AS YOU KNOW, WE GIVE ALMOST EVERYBODY $250,000 WHICH IS THE MAXIMUM FOR DSI. PRETTY MUCH EVERYTHING GETTING THE SAME THING. >> I WAS THINKING AS ESIs COME UP FOR RENEWAL IT SEEMS LIKE A PLACE WHERE -- >> YOU'RE RIGHT. IT'S A CONCERN AND SOMETHING WE HAVE TO LOOK AT CLOSELY. YOU ALSO RAISED A GOOD POINT AND OUR INTENTION IS SOME E.S.I.s WILL GET BIGGER BUDGETS BECAUSE THEIR PROGRAM NEEDS IS JUSTIFIABLY EXPANDED SOMEWHAT. >> RON. >> AND PUSHING THE REFERRAL PROGRAM. NOT SURE IF YOU MENTIONED THIS OR NOT AS APPLICATIONS COME THROUGH AND ABILITIES GROW, IS THERE AN ANGLE OF NOT ALLOWING SAY FOR EXAMPLE SOME NEW TECHNOLOGY, NEW IDEAS TO FALL THROUGH THE CRACKS BECAUSE THEY DO NOT RUN UNDER THE SAME THAT WAS ESTABLISHED. >> CAN YOU ELABORATE? >> YOU'VE GOT THE STEADY STATE OF SCIENCE NOW. YOU UNDERSTAND THE CATEGORIES AND ALL THAT. SOMEBODY COMES IN SAY FOR EXAMPLE FOR TOMOGRAPHY AND THE KNOWLEDGE BASE MAY NOT BE AS EVOLVED AND CATEGORIZED, WOULD YOU BE WORRIED. >> THOSE ARE SOMEWHERE YOU LOOK AT IT AND SAY WHAT IS THIS THING. IT MAY BE THE DETAUGHT -- DEFAULT PERSON THAT LOOKS AT THE ODD BALLS. I CALL IT THE DARK MATTER OF SCIENCE. IT'S THE DIFFICULTY OF MACHINE LEARNING THAT IT NEEDS A SET TO HAVE STARTED WITH SOMETHING NEW. ALL RIGHT. SO THANK YOU ALL FOR GREAT DISCUSSION. WE'RE GOING TO MOVE ON NOW TO THE NEXT STEP WHICH IS ROECHELLE TALKING ABOUT THE NIGMS REPORT ON SEPSIS. >> GOOD MORNING. I'LL GIVE AN OVERVIEW AND WE'LL HAVE TIME FOR DISCUSSION AND I INVITE YOUR COMMENTS. I'M HERE TO SPEAK TO YOU ABOUT SEPSIS, WHICH IS A RAPIDLY DEVELOPING PROGRESS HETEROGENEOUS DISORDER. IT'S COMMONLY REFERRED TO AS THE BODY'S OVERWHELMING IMMUNE RESPONSE TO INFECTION. MORE PRECISELY DESCRIBED IN JAMA BY TO THE THIRD CONSENSUS CONFERENCE OF EXPERTS AS A LIFE-THREATENING ORGAN FUNCTION BY A DEGREE -- DYSREGULATED HOST RESPONSE TO THE INFECTION. AND THEY DESCRIBED THIS CAUSES AS MUCH AS 1.7 MILLION CASES ANNUALLY, OVER 270,000 DEATHS PER YEAR AND RELATED TO 1 IN 3 HOSPITAL DEATHS IN THE UNITED STATES SO THE IMPACT IS CONSIDERABLE. NOW, YOU ALREADY KNOW NIGMS IS ONE OF SEVERAL INSTITUTES THAT SUPPORTS SEPSIS RESEARCH, PARTICULARLY BECAUSE IT AFFECTS MULTIPLE ORGAN SYSTEMS. WE'RE NOT DEDICATED JUST ONE AND ACTS IN A COMPLEX AND DYNAMIC WAY. IT ALSO INVOLVES THE HOST INFLAMMATORY RESPONSE BY ACTIVATED CELLS OF THE INNATE IMMUNE SYSTEM. SO LAST YEAR, LEADERSHIP AT NIGMS CONVENED A WORKING GROUP OF COUNCIL. THEY ASKED FOR ADVICE ON NIGMS FUNDING OPPORTUNITIES AND WHERE TO MAKE INVESTMENTS. THE GROUP GENERATED A REPORT. YOU CAN FIND IT ONLINE BY LOOKING AT OUR WEB PAGE AND GOOGLING OUR NEWS AND REPORTS. FURTHERMORE, JOHN YOUNGER AND MONICA KRAFT PRESENTED LAST YEAR TO COUNCIL. IF YOU GOOGLE OUR FEEDBACK LOOP ON SEPSIS AND YOU CAN SEE WHERE TO IMPROVE THE IMPACT IN MAKING PROGRESS IN THIS DISEASE AREA. THESE ARE THE WORKING GROUP MEMBERS. WHAT I MOST WANT YOU TO NOTE IS THEY COME FROM A VARIETY OF BACKGROUNDS. YOU HAVE CLINICIANS, YOU HAVE BASIC RESEARCHERS AND PEOPLE FROM ACADEMIA, PEOPLE FROM INDUSTRY. PEOPLE FROM THE FIELD OF SEPSIS AND PEOPLE OUTSIDE THE FIELD OF SEPSIS. I THOUGHT WORKING TOGETHER THEY CONTRIBUTED NEW INSIGHTS AND NEW WAYS FOR NIGMS TO THINK ABOUT HOW WE THINK ABOUT SEPSIS RESEARCH. THEY HAD FIVE SPECIFIC RECOMMENDATIONS BY FAR THE MOST MAJOR IS THE FIRST ONE. THEY RECOMMENDED WE SIGNIFICANTLY EXPAND OUR SUPPORT OF CLINICAL RESEARCH. BY THAT I MEAN TO REBALANCE OUR PORTFOLIO TO HAVE MORE OF A CLINICAL FOCUS. TO FOCUS SPECIFICALLY ON PATIENTS, MATERIALS DERIVED FROM PATIENTS AND TRULY UNDERSTAND THE COMPLEXITY AND HETEROGENEITY OF THE DISEASE BECAUSE IT'S PEOPLE THAT GET SEPSIS. THAT'S WHERE WE WANT TO MAKE PROGRESS. ADDITIONALLY THEY COMMENTED WE SHOULD STRENGTHEN OUR COLLABORATIONS WITH OTHER INSTITUTES AT NIH AND RECOMMENDED WE BROADEN OUR TRIALS BECAUSE IF WE DO, A TRIAL IS DIFFICULT TO ADMINISTER AND THOUGHT WE SHOULD PLAY INTO OUR STRENGTHS AS AN INSTITUTE AND RECOMMENDED WORKING WITH THE NIH CENTER FOR SCIENTIFIC REVIEW AND COORDINATING AT THE HIGHEST LEVELS AT NIH. THE REPORT WHICH IS ACCESSIBLE, HAD SEVERAL RECOMMENDATIONS IN THE PRE-CLINICAL, CLINICAL AND TRANSLATIONAL AREAS. CHIEF AMONG THEM ARE LOOKING AT BIOSPECIMENS AND BIOMARKERS AND CLINICAL DATA SETS AND OTHER MATERIALS THAT COULD BE USED TO STRENGTHEN OUR INVESTMENT INTO CLINIC RESEARCH. SO WE TALKED INTERNALLY AND PLANNED TO RESPOND. WE HAVE DEVELOPED SETS OF RECOMMENDATIONS THAT PLACE AN MEMPHIS ON PATIENT-DERIVED MATERIALS WORKING BEDSIDE TO THE BENCH AND INCREASE OUR MECHANISTIC UNDERSTANDING IN PATIENTS AND BETTER CATEGORIZE SUBTYPES OF SEPSIS PATIENTS AN EMPHASIZE SCIENCE AS IS OUR STRENGTH FOR FUTURE STUDIES AND TRANSLATIONAL APPLICATION. ADDITIONALLY, PLAY TO STRENGTHS WE HAVE IN THE INSTITUTE IN THE COMPUTATIONAL MODELING AND INFO INFORMATICS AREAS AND LOOKING AT MODELS FOR UNDERSTANDING SEPSIS IN HUMANS. AND FIN -- FINELY A SUITE OF PROGRAMS. WE COULD XLZ -- CAPITALIZE ON THOSE AND WE SET ABOUT HOW TO FOCUS ON SEPSIS IN MORE TARGET AND STRATEGIC WAYS. FIRST THING WE DID WAS TO PUBLISH A NOTICE TO DESCRIBE THE PRIORITIES FOR SEPSIS RESEARCH AND PUBLISHED THIS SUMMER. IN IT WE EMPHASIZED, AGAIN, SETS OF POINTS OR PRIORITIES OR PURPOSE IN WORKING TO UNDERSTAND THE PATHOPHYSIOLOGY OF THE DISORDER IN PATIENTS. AT THE MOLECULAR, CELLULAR, WHOLE PERSON LEVEL. WE'RE INTERESTED IN RESEARCH THAT ADDRESSES THE RAPID IDENTIFICATION AND CLASSIFICATION OF DIFFERENT KINDS OF SEPSIS PATIENTS WHO HAVE DIFFERENT OUTCOMES. WE'RE VERY INTERESTED IN MECHANISTIC STUDIES WITH PATIENT DERIVED MATERIALS. ADDITIONALLY CAPITALIZING ON OUR COMPUTATIONAL STRENGTHS WE'RE INTERESTED IN WORKING WITH ELECTRONIC HEALTH RECORDS FOR PREDICTIVE ALGORITHMS AND COMBINING DATA TYPES AND THE APPLICATION OF CUTTING EDGE SCIENCE AND ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING. ADDITIONALLY, WE'RE STRENGTH STRENGTHENING OUR USE OF NON TRADITIONAL MODELS AND NEW MODELS TO STUDY SEPSIS. ADDITIONAL PRIORITIES INCLUDE ENCOURAGING OMICS APPROACHES TO MATERIAL AND PATIENTS WE CAN OBTAIN ACCESS TO. FINALLY THE DEVELOPMENT OF ASSAYS THAT MAY HAVE BEDSIDE UTILITY AND BIOMARKERS THAT MAY BE BENEFICIAL TO EVALUATE FUTURE DIAGNOSTICS AND INTERESTED IN COMORBIDITY THAT CONTRIBUTE TO SEPSIS AND HOW THEY MAY DISCERN SEPSIS OUTCOME. FINALLY, IN ORDER TO HAVE INCREASED PRIORITY ON SOME THINGS, WE HAVE TO HAVE LOWER PRIORITY ON OTHER THINGS. WE ARE CHOOSING TO DEEMPHASIZE AND WELL JUSTIFIED TO UNDERSTAND THE TRAJECTORY IN HUMANS AND CLINICAL TRIALS AT THE LARGER SCALE. AND HYPOTHESIS ARE FOUND IN PRELIMINARY DATA AND CLEAR CHANCE OF GIVING US A SPECIFIC AND UNIQUE ANSWER. ADDITIONALLY WE PUBLISHED A REQUEST FOR INFORMATION. IT'S THE TYPE OF NOTICE WHERE WE ASKED THE COMMUNITY TO RESPOND AND WOULD LIKE ANSWERS TO THE QUESTIONS WE WANT TO ASK IDEALLY WITHIN THE NEXT FEW MONTHS OF THIS COUNCIL DATE. WE'RE INTERESTED IN WHETHER WE SHOULD STIMULATE A REPOSITORY AND WHAT TYPES OF MATERIALS MAY BE COLLECT AND STORED AND WHAT'S REASONABLE, PRACTICAL AND ACCESSIBLE. AND WE'RE INTERESTED IN THE OPTIMUM PATIENT POPULATIONS TO OBTAIN THE MATERIALS FROM. WHERE WE MIGHT BE ABLE TO GET MATERIALS AND LINKED CLINICAL DATA. WHAT ARE SOME OF THE CHALLENGES WE'D FACE. THEY'RE WELL KNOWN WITH THE RAPIDLY PROGRESSING AND DIFFICULT CARE SITUATION. YOU HAVE TO CONSIDER CONSENT AND CONFIDENTIALITY AT ALL TIMES. GIVEN THERE ARE EMERGING TECHNOLOGIES HOW SHOULD MATERIALS BE PREPARED AND STORED AND WHAT SPECIALIZED PROTOCOLS MIGHT BE NEEDED. ARE THERE EXISTING MATERIALS AND REPOSITORIES. WE DON'T WANT TO RUSH TO CREATE SOMETHING IF IT ALREADY EXISTS SOMEWHERE AND WHAT LESSONS COULD WE USE TO OTHER MATERIALS AND BIOSPECIMEN. IF YOU TAKE HOME ONE THING FROM THIS TALK IS TELL PEOPLE ABOUT THE NOTICE OF PRIORITIES AND FOR REQUESTING INFORMATION AND ENCOURAGE PEOPLE TO PASS IT ALONG AND RESPOND EVEN FROM INVESTIGATORS WHO MAY NOT HAVE TRADITIONALLY CONSIDERED THEMSELVES MEMBERS OF THE SEPSIS RESEARCH COMMUNITY. WE'RE CURRENTLY REACHING ON OUTREACH PLANS. WE WANT TO SPEAK TO CURRENT AWARDEES AND SPEAK TO POSSIBLE NEW AWARDEES. WE WANT TO SPEAK TO PEOPLE WHO HAVE METHODS AND APPROACHES WHO HERE TO FOR MAY NOT OF THOUGHT OF APPLYING TO SEPSIS. WE SPEAK THROUGH THE FEEDBACK LOOP BLOG AS YOU KNOW. AS PROGRAM DIRECTORS WE FOLLOW-UP WITH CLIENTELE, OUR CONSTITUENCY. WE'RE WORKING TO GET PERSONAL MESSAGES OUT INCLUDING INVITING PEOPLE TO THINK ABOUT SEPSIS RESEARCH AND TO THINK AND RAISE AWARENESS WITH INVESTIGATORS WHO MAY BE AFFECTED BY THE REMARKETPLACING OF THE PORTFOLIO -- REBALANCING PORTFOLIOS TO THINK AHEAD TO THEIR PRIORITIES. WE'RE PLANNING OUTREACH AT SCIENTIFIC MEETING AND LOOKING TO GET OUR MESSAGE TO A WHOLE COLLECTION OF CLIENTS OR APPLICANTS OR POTENTIAL FUTURE RESEARCHERS IN THE AREA. WE HOPE TO REACH OUT TO RESEARCH SOCIETIES AND THOSE WHO USE RESEARCH ORGANISMS AND COMPUTATIONAL RESEARCHERS AND THOSE IN THE BIOENGINEERING COMMUNITY. I WELCOME ANY INPUT FROM ANY OF YOU HOW TO BEST REACH PEOPLE WHO YOU KNOW WHO MAY POTENTIALLY BE INTERESTED. WE DID FOLLOW-UP ON SPEAKING ACROSS LEADERSHIP AT NIH. JOHN LORSCH MET WITH THE OFFICE OF THE DIRECTOR AND LEADERSHIP AT ALLERGY AND INFECTIOUS DISEASE, HEART LUNG AND BLOOD INSTITUTE, KIDNEY DISORDERS AND THE MORE LIFE SPAN INSTITUTES, CHILD HEALTH AND THE INSTITUTE OF AGING AS WELL AS THE NATIONAL INSTITUTE FOR TRANSLATIONAL RESEARCH. THEY AGREED TO CONVENE A DIVISION DIRECTOR'S LEVEL GROUP AND PLAN TO COORDINATION AND TAKE ACTION. AMONG SOME THINGS WE HAVE PLANNED ARE INVENTORYING EXISTING BIOSPECIMEN SETS OR REPOSITORIES, IDENTIFYING CLINICAL NETWORKS AND WHERE DATA SETS EXIST THAT MAY BE OF INTEREST TO OUR PRIORITIES. SHOULD WE ENGAGE IN CLINICAL TRIALS MIGHT BE EFFICIENT AND EFFECTIVE. WE ALSO WANT TO GATHER AS ALL THE INSTITUTES REACHING OUT TO THE CENTER FOR SCIENTIFIC REVIEW TO AID SROs IN WHERE NEW APPLICATIONS MIGHT COME IN OR WHERE EXPERTISE MAY BE USEFUL FOR REVIEW GROUPS AND DOUBLE DOWN AND I THINK WE COORDINATE BUT WORK HARDER ON COORDINATING EFFECTIVELY ACROSS NIH INSTITUTES AND CENTERS. IF WE CAN MAKE ONE CLEAR STATEMENT IT'S PLAN TO PROCEED WITH THE RECOMMENDATIONS OF THE WORKING GROUP. I DIDN'T DO THIS IN A VACUUM. I'M NOT AN EXPERT ON SEPSIS. WE HAVE A TRANS-GROUP WORK ON THIS AND WANT TO CONGRATULATE THOSE WHO WORKED ON THE PRIORITY AND SCOTT SOMERS FOR THE REQUEST FOR INFORMATION FOR POTENTIAL GREATER UNDERSTAND HOW LONG WE MIGHT CONSIDER A BIOREPOSITORY OR BIOSPECIMENS. TOGETHER THESE INDIVIDUALS HAVE QUITE A BIT OF EXPERTISE IN THE SUBJECT OF SEPSIS, SHOCK AND ORGAN FAILURE, IMMUNE MECHANISMS, ALL THE OTHER SCIENTIFIC DISCIPLINES, INFORMATICS, RESEARCH ORGANISM, DATA ANALYSIS, GENOMICS, TECHNOLOGY, SMALL BUSINESS AND ON. TOGETHER WE'RE WORKING TO IMPLEMENT THE RECOMMENDATIONS AND I THINK WE'LL MAKE A DIFFERENCE AND IMPACT THE AREA OF SEPSIS RESEARCH. AND WITH THAT, I INVITE YOUR QUESTIONS. >> THANK YOU, ROCELLE. >> WE CAN START WITH THE WORKING EMBERS. THAT'S GREAT. WE SPENT A LOT OF TIME GOING BACK AND FORTH AMONG THE WORKING GROUP ABOUT HOW POSITION THESE RECOMMENDATIONS AND EMPHASS IN HOW TO GO ABOUT IT. THIS IS A WHAT WE WOULD HAVE IMAGINED IN THE BEST CASE SCENARIO PUTTING THIS TOGETHER. THERE'S NO DOUBT THERE'S WORK TO BE DONE AND NO QUESTION. I ACKNOWLEDGE BOTH YOU AND ALSO SARAH AND SCOTT. I SUSPECT THERE'S A LOT OF PHONE CALLS THAT ARE GOING ON RIGHT NOW HOW BEST TO BE RESPONSIVE. I'M REALLY EXCITED. IT'S GREAT. THANKS. I THINK THE FIELD IS REALLY APPRECIATE OF THE TIME YOU GUYS HAVE SPENT TRYING TO WORK THROUGH SOME OF THESE QUESTIONS AND IT'S REALLY APPRECIATED. >> THANKS FOR THE OVERVIEW. IT'S A RAPID RESPONSE TO THE REPORT. CONGRATULATIONS FOR THE THOUGHTFUL AND PURPOSEFUL RESPONSE TO THE COMMITTEE AND SHORT CYCLE TIME. IT'S A COMPLEX BASE AS YOU ARTICULATED AND A BROAD FRONT WE PAINTED THERE. I GUESS ONE OF THE QUESTIONS IS AT WHAT PERIOD SHOULD WE ALL EXPECT PROGRESS UPDATE OF THE TRACTION THAT THESE TACTICS YOU PUT IN PLACE AND WHICH ONES ARE WORKING AND WHICH ONES ARE NOT BECAUSE HISTORY TEACHES WHATEVER WE PLAN IS NOT ACTUALLY WHAT'S GOING TO HAPPEN AND SO WHAT'S THE COURSE DIRECTION MODEL YOU HAVE IN MIND AS WE PROGRESS INTO THESE EFFORTS. >> I WOULD ANSWER IT'S MULTIPRONG. PEOPLE NEED TO MEET AND TRY IT ON FOR SIZE. PEOPLE NEED TO CONSIDER WHETHER THEY ARE CAN HAVE PRODUCTIVE INTERACTIONS. FROM MY EXPERIENCE, YOU CAN INTRODUCE PEOPLE TO ONE ANOTHER SO THAT'S THE LONG RANGE GOAL. IN THE SHORT RANGE GOAL, I THINK MAKING FUNDING DECISIONS FOR PEOPLE WHO CURRENTLY WORK IN SEPSIS AND TRYING TO EMPHASIZE PATIENT DEVIVED MATERIALS AND APPLICATIONS OF MATERIALS ARE THINGS WE CAN'T ACCOMPLISH WITH THE APPLICATIONS WE HAVE COMING I AND IT'S IMPORTANT TO WORK WITH PEOPLE IN THE SHORT TERM AND MAYBE HAVE THOUGHT ABOUT APPROACH THINGS IN OTHER WAY AND HOW THEY MIGHT REPOSITION THEMSELVES TO COMPETE FOR RENEWALS. WE'D LIKE TO STIMULATE POSITIVE THOUGHT AND WOULD LIKE THAT TO HAPPEN IN THE NEAR FUTURE IN THE NEXT MONTHS AND YEARS AND WE'LL BE ABLE TO ASSESS THE TYPES OF APPLICATIONS WE FUND HOPEFULLY SEE A DIFFERENCE AS EARLY AS A YEAR FROM NOW. IT'S NOT FLASH IN THE PAN. >> THANK YOU. THIS IS REALLY INTERESTING. I OFTEN HEAR RESEARCH IS SEARCHING WITH A LOT OF REACH. IF YOU'RE GOING TO DO THE SAME THING OVER AND OVER AGAIN YOU'LL FIND THE SAME THING OVER AND OVER AGAIN. THIS IS DRAMATICALLY DIFFERENT AND GOING TO BE I THINK THE ANSWER WE'RE ALL SEARCHNG FOR. >> CATHY. >> THANK YOU FOR THE REPORT. IT'S WONDERFUL YOU HAVE BROUGHT IN AREAS THAT REQUIRE CROSS INSTITUTIONAL COLLABORATION. ONE THING OF INTEREST IS YOU ARE TALKING ABOUT YOU WOULD LIKE TO START USING CUTTING EDGE TECHNOLOGY TO FACILITATE INFORMATICS AND INFORMATION OF PREDICTIVE MODELING WE'D LIKE TO COLLECT CLINICAL DATA AND GENOMIC DATA FOR DIFFERENT TYPE OF ANALYSIS. SO ONE QUESTION I HAVE IS SO IN THE R.F.A. YOU REQUEST FEEDBACK BUT YOU MENTION YOU'D LIKE TO GET DATA SETS FOR THINGS OF THAT NATURE. IS THERE AN R.F.I. WOULD YOU EXPAND TO REQUEST THAT TYPE OF INFORMATION. >> YU'RE ASKING ABOUT DATA SETS AND INFORMATION AVAILABLE. I ENCOURAGE ANYONE THINKING ALONG THOSE LINES TO RESPOND TO THE REQUEST FOR INFORMATION NOW. THERE ARE BLOCKS, GET IT IN. WE'LL ANALYZE THE RESPONSES. I THINK THOSE PERSONALLY INVOLVED IN THE RESEARCH FIND IT'S IMPORTANT WHEN BIOSPECIMENS ARE OBTAINED DATA IS OBTAINED AT THE SAME TIME. THEY NEED TO BE LINKED. FEEDBACK MAY SAY IT NEEDS TO BE DONE AT INDIVIDUAL ORGANIZATIONS TO CONTROL THE SENSITIVE DATA AND ACCESS TO IT. THAT'S WHY WE WANT TO GET FRANK AND COMPLETE RESPONSE TO THE R.F.I. I THINK WE WANT DATA SETS TO BE THE MOST VALUABLE. THEY'LL HAVE IDENTIFYING INFORMATION IN THEM. OR SOME REALLY THOUGHTFUL APPROACHES TO IDENTIFYING INDIVIDUALS. I THINK THAT WILL BE NEEDED IN ORDER TO MAKE PROGRESS. I DON'T THINK IT'S SPECIMENS ALONE. WE DON'T HAVE A BANK TO MAKE TRUE SUBSTANTIAL PROGRESS. WE WANT TO FIND OUT FROM RESPONDENTS FROM ANY BACKGROUND HOW TO BEST ACCOMPLISH THIS IF IT CAN BE DONE. >> CONFIDENTIALITY IS EXTREMELY IMPORTANT AND MUST BE MAINTAINED. THAT'S SOMETHING SUSAN IS WORKING ON HARD TO FIND BETTER WAYS TO ALLOW ACCESS TO DATA BUT MAINTAINING CONFIDENTIALITY AND PREVENTING REIDENTIFICATION. SARAH. >> SO FROM AN INDUSTRY PERSPECTIVE, WE HAVE SEEN A LOT OF RESEARCH IN THIS FIELD AND WE'RE FAMILIAR WITH SOME OF THE CLINIC FAILURES. THE PROSPECTIVE THAT MAY BE USEFUL THERE'S ACTIVITIES DONE AND NEVER PUBLISHED BECAUSE THEY FAILED AND A LOT OF THOSE PEOPLE WHO DID THAT WORK WHO WOULD HAVE A LOT OF INSIGHT ON WHAT THE HURDLES WERE HAVE BEEN REPURPOSE AND NOT IN THE FIELD ANYMORE. THEY WOULD NOT BE MEMBERS OF THAT ASSOCIATIONS THAT YOU'RE REACHING OUT TO OR SEE THOSE KIND OF PUBLICATIONS. I'M WONDERING IF THERE WOULDN'T BE A WAY TO COORDINATE AN EFFORT TO TRY TO TAP INTO SOME OF THOSE PEOPLE WHO HAVE BEEN THWARTED SO WE DON'T KEEP BEATING OUR HEADS AGAINST THE WALL OVER THINGS THAT DERAILED. >> GREAT POINT. HOW DO WE GET ACCESS TO THOSE PEOPLE IN INDUSTRY WHERE THEY'RE WORKING ON SOMETHING ELSE NOW AND MAYBE THE INFORMATION IS ACTUALLY PROPRIETARY? >> I THINK WE HAVE TO TAP INTO OUR NET WORKS. I DON'T KNOW HOW WE PROCEED WITH THAT. YOU PROBABLY KNOW SOME PEOPLE IN THAT FIELD. >> I WOULD THINK THE PROCESS IS PEDANTIC AND GET PEOPLE TO LIST NAMES AND START PULLING THREADS WITH PERSONAL PHONE CALLS AND THAT SHOULD START THE GROUND SWELL, OTHER THAN THAT, THERE'S PROBABLY NO SYSTEMATIC WAY OF DOING THAT THAN SHOE LEATHER. >> FAILED WORK NEVER SEES THE LIGHT OF DAY. >> IF YOU CAN TELL US WITH WHOM WE MIGHT SPEAK OR INTRODUCTIONS SAYING WE MEAN NO HARM, I CAN GUARANTEE YOU WE FOLLOW-UP. OUR PURPOSE IS TO GAIN INFORMATION AND THINK CRITICALLY ABOUT WHAT WE KNOW AND DON'T KNOW. THERE'S SOME INFORMATION WE WON'T HAVE ACCESS TO BUT THERE MAY BE KNOWLEDGE GLEANED PEOPLE WANT TO SHARE IF THEY WANT TO HELP US MAKE PROGRESS THROUGH OUR TOOLS AND FUNDING RESEARCH GRANT APPLICATIONS. >> WOULD AN R.F.I. TARGETED PRODUCING RESULT OR WOULD THEY NOT RESPOND? >> I DON'T THINK THEY WOULD SEE IT. I THINK MOST PEOPLE FEEL PASSIONATE IT'S A HORRIBLE PROBLEM THAT NEEDS TO BE ADDRESSED AND I THINK THEY'D BE THRILLED BY EFFORTS GOING ON HERE AND LOOKING AT WHAT WE'RE LOOKING AT. WE ALL KNOW ANIMAL MODELS DON'T WORK AND WE ALL KNOW WE DON'T HAVE GOODIOR -- GOOD BIOMARKERS AND GOOD WILL FROM PEOPLE WANTING TO SEE EFFORTS PROCEED IF WE GET IN TOUCH WITH PEOPLE. STRAND GET TO THE >> AND GET TO THE RIGHT PEOPLE IN INDUSTRY TO RESPOND. GOOD IDEA. >> AS YOU TALK ABOUT THE COMMON DATA SETS, HAVE YOU GIVEN THOUGHT TO COMMON DATA PLATFORMS TO THE DATA CAN BE MADE IN SUCH A WAY THAT VARIATION BRANCHES OF OMICS CAN SAVE MORE TIME AND CODING AND THOSE KINDS OF THINGS SO YOU CAN CUL OUT CRITICAL INFORMATION QUICKLY? >> I WOULD SAY THAT'S SUSAN'S NEW JOB. >> WE'RE THINK OF INTEGRATING DISPARATE DATA SETS. IT DOESN'T MEAN YOU IMMEDIATELY PUT EVERYTHING ONLINE BUT YOU THINK HOW INSTITUTIONS AND ORGANIZATIONS ARE COLLECTING AND STORING THEIR DATA, TAKING ADVANTAGE OF PLATFORMS THE GOVERNMENT OFFERS AND WE'LL BE OFFERING TO SHARE DATA AND THOSE INDIVIDUALS HAVE TO BE MOTIVATED TO DO SO. START BY FIGURING OUT WHAT DATA ARE THERE AND WHAT MIGHT BE SHARED FOR SCIENTIFIC UTILITY, ARE PEOPLE MOTIVATED TO DO IT AND HOW DO WE MAKE IT HAPPEN. IT'S A MULTI-STEP PROCESS. >> IT'S ONE REASON I THINK THE WORKING GROUP WORK CLOSELY WITH OTHER INSTITUTES THAT HAVE A FOOTPRINT IN THIS AREA BECAUSE IT PROBABLY DOESN'T MAKE SENSE FOR EACH INSTITUTE TO STAND UP ETCETERA AND THAT'S PART OF THE DISCUSSION WE'RE HAVING. PART OF WHY THE R5s ARE FOR THE COLLECTION OF SAMPLES AND THE OTHER SIDE IS DATA INFORMATION. >> I'M WORKING ON MY RESPONSE TO THE RFI. NOT RIGHT NOW BUT SOON. ONE THING THERE'S AN OPPORTUNITY FOR NEW THINKING IN TERMS OF THE BIOREPOSITORY. ONE OF THE THINGS THAT CLEARLY CAME OUT OF OUR DISCUSSIONS IS A LOT OF THESE NEW DRUGS ARE GOING TO BE USEFUL AND WILL BE IDENTIFIED QUICKLY AND THIS CAME UP IN OUR DISCUSSION LAST TIME, WHAT'S POSSIBLE IN HALF AN HOUR IN TERMS OF TECHNOLOGY. YOU CAN INVOKE TECHNOLOGIES IN THE FUTURE THAT WILL BE ABLE TO DO AMAZING THINGS IN 30 MINUTES BUT THAT'S NOT THAT EXISTS NOW. ONE WAY TO ENGAGE PEOPLE'S THINKING IN WHAT CAN BE DONE RAPIDLY IS TO PUT AN EMPHASIS ON A BIOREPOSITORY THAT EXIST INS REAL TIME. IF I CAN GET A LOBSTER LIVE TO MY FRONT DOOR I SHOULD BE ABLE TO GET A PLASMA SAMPLE FROM ACROSS THE COUNTRY OR LIVING SAMPLE OF BLOOD CELLS QUICKLY TO DO WORK ON. I THINK THINKING AND I KNOW THERE ARE BIOREPOSITORY PROGRAMS THINKING OF REAL TIME DELIVERY OF MATERIAL TO DISTRIBUTE THAT ACROSS THE COUNT TRY TO RESEARCHERS. I THINK THINKING ABOUT WHAT TYPE OF SAMPLES WHAT SHOULD THE BALANCE BE BETWEEN A BANK OF FREEZE FREEZERS NIGMS OWNS FOREVER AND ANOTHER FACILITY COULD DO ANALYSIS TO PATIENT SAMPLES THEY WOULDN'T HAVE OTHERWISE HAD ACCESS TO AND THERE'S REAL OPPORTUNITIES FOR LIVING MATERIAL TO BE ANALYZED. THAT'S WHAT PEOPLE DO WITH ROW DEBTS ALL THE TIME. -- RODENTS ALL THE TIME. THINKING OF HOW BEST TO DEFINE WHAT A BIOREPOSITORY IS IS AN INTERESTING OPPORTUNITY. >> I BET THE LOGISTICS OF TRANSPORTING SAMPLES IS PROBABLY THE LEAST OF THE PROBLEMS. BECAUSE THAT LOB TER DOESN'T HAVE A FAMILY AND PEOPLE ARE CRITICALLY ILL WHO HAS A FAMILY THAT NED TO CONSENT. -- NEEDS TO CONSENT. I DON'T WANT TO ACKNOWLEDGE THE ENORMITY OF THE PROBLEM AND IF A SMALL GROUP WANTS TO START BY SHARING I THINK IT'S VERY IMPORTANT TO HAVE THE LINKED CLINICAL INFORMATION AND THOUGHTFUL APPROACHES TO WHAT YOU COLLECT, DOING IT RIGHT IS THE MOST IMPORTANT THING. I THINK IF YOU DEVELOP RESOURCES IT'S VALUABLE TO RESEARCHERS, THEY'LL USE IT. THE KEY IS CAN YOU DEVELOP SOMETHING ENORMOUSLY VALUABLE? >> THIS IS REALLY EXCITING. IN THE FIELD OF PEDIATRICS SEPSIS WE HAVE LITTLE DATA AND A LOT OF IS CONFLICTING. I'M HOPING THROUGH THIS BIOREPOSITORY WORK AND OTHER THINGS, WE'LL BE ABLE TO INFORMATION WHY WE GET A DIFFERENT ANSWER WHEN WE DO THE TRIAL THREE DIFFERENT TIMES. IS IT THE TIMING, DOSE, THE SUBSET OF PATIENTS THAT CAN HELP GUIDE THE NEXT STUDY BUT I THINK A NATURAL CONSEQUENCE OF THE LEARNING THAT'S GOING TO HAPPEN IS GOING TO BE THERE WILL BE THE DATA TO DRIVE THE NEXT CLINICAL TRIAL AND I UNDERSTAND THAT'S NOT THE FOCUS NOW BUT IS THERE A WAY TO HAND THIS TO THE NEXT INSTITUTE SO THAT ONCE THOSE DATA ARE RIPE AND WE NEED TO DO A NON-MECHANISTIC CLINICAL TRIAL OR NEW OR OLD THERAPY IN A NEW WAY, IT WILL BE FACILITATED. >> I THINK YOU PICKED UP AN IMPORTANT POINT THE WORKING GROUP WANTED TO MAKE. HOW CAN WE LAY THE GROUNDWORK FOR GREAT CLINICAL TRIALS IN THE FUTURE AND THEY MAY NOT BE OUR TRIALS BUT IF WE HAVE A FUNDAMENTAL INFORMATION OF THE ORDER IT WILL ENABLE THE GROUP TO DESIGN THE RIGHT TRIAL AND THERE'LL BE ANOTHER NIH INSTITUTE INTERESTED AND THAT IS GETTING AHEAD OF OURSELVES TO DO THAT NOW TO THINK ONE TRIAL WILL SOLVE ALL THE PROBLEMS. THAT'S WHAT THE WORKING GROUP SPEND THEY SET CONCENTRATE ON YOUR STRENGTHS IN UNDERSTANDING THE DISORDER. >> A TWO-PART QUESTION. IN YOUR INTERACTION WITH PEERS FROM OTHER INSTITUTES, WE SAW THE SUMMARY OF THE THINGS THAT WAS AGREEMENT TO AND IT DOESN'T NECESSARILY MEAN ENERGY AND ENTHUSIASM SO WONDERING IF YOU CAN ADD COLOR TO THE LEVEL OF EMBRACEMENT. >> THERE WAS QUITE A BIT OF ENTHUSIASM. SO FRANCIS COLLINS WHO I FIRST SPOKE TO IS INTERESTED AND CONCERNED AND WANTS TO SEE PROGRESS IN THE FIELD AND WAS SUPPORTIVE OF WHAT THE WORKING GROUP PROPOSED AND WHAT WE RESPONDED TO SO FAR AND IT WAS HE WHO ASKED THEY CONVENE ALL THESE I.C. DIRECTORS TO GET TOGETHER AND TALK. EVERYONE IN THE DISCUSSION SEEMED TO THINK WHAT WE WERE DOING IN RESPONSE TO THE REPORT WAS CORRECT WAS ENTHUSIASTIC IN FINDING WAYS TO FIND SYNERGIES AND ECONOMIES OF SCALE AND SAMPLE COLLECTION AND THE PLATFORMS AS BILL MENTIONED EVENTUALLY IN CLINICAL TRIALS AND THAT'S WHAT THE DISCUSSION THE DIVISION DIRECTORS GROUP WILL BE WORKING ON. WHAT ARE THE BEST OPPORTUNITIES FOR US TO SLOT INTO WHAT'S ALREADY GOING ON. I DON'T THINK THERE'S LACK OF INTEREST OR ENTHUSIASM BUT IT'S A QUESTION OF HOW DO YOU GET EVERYONE MOVING IN THE MOST SYNERGISTIC DIRECTION WHEN THEY HAVE THEIR OWN INDEPENDENT MISSIONS AS WELL. >> SO AS A FOLLOW-UP QUESTION TO THAT, IN TERMS OF GETTING DEEPER INTO THEIR ORGANIZATIONS OR THEIR ADVISORY BOARDS, YOU VERY EFFECTIVELY USED INVITATIONS TO PEER INSTITUTE TO HAVE PRESENTATIONS OF THEIR FOCAL AREAS. IS THERE AN OPPORTUNITY TO DO THE JOHN AND ROCHELLE ROAD SHOW? >> USUALLY IT'S BEEN INVITATION ONLY BUT IT'S SOMETHING WE CAN WORK ON. >> I THINK THE GROUNDWORK HERE TO ELICIT THE CONVERSATION DEEPER IN THE ORGANIZATION AND NOT JUST HAVE IT AT THE TO THE HOUSE IS IMPORTANT FOR MOMENTUM. >> I SHOULD STRESS IN ADDITION TO THE DIVISION DIRECTOR LEVEL GROUP ROCHELLE WILL BE A PART OF THERE WAS A PROGRAM DIRECTORS LEVEL GROUP SARAH DUNSMOOR WAS PART OF AND THAT CONTINUES. >> THERE'S DEDICATED INTERESTED PEOPLE AT THE GRASSROOTS LEVEL. I HOPE WE CAN ENABLE THEM TO ACCOMPLISH EVEN MORE. >> COMING BACK TO PATIENT CONFIDENTIALITY AND REPOSITORIES AND SO ON, IF I UNDERSTAND THE BIOLOGY OF IT, DIFFERENT PATIENTS RESPOND DIFFERENTLY TO SEPSIS. SOME REALLY QUICKLY. THERE'S VARIATION. IS THERE EVIDENCE TO SUGGEST THERE'S AN UNDERLYING GENETIC DIFFERENCE TO THE PROBLEMS AND IF THERE IS, I'M NOT SURE THE DATA ANALYSIS IS TAKING THAT INTO ACCOUNT OR WILL PLAN TO HAVE SOME SORT OF DNA ANALYSIS OR SOMETHING LIKE THAT. >> THAT'S PART OF THE PLAN THE OMICS STRONG PART OF IT, PROTEOMES, METABOLOMICS AND OMICS THAT HAVEN'T BEEN DESCRIBED YET BUT GENETIC COMPONENTS ARE A POSSIBILITY STILL. >> THERE'S BEEN SNIPS IN LITERATURE AND [INDISCERNIBLE] I THINK WHAT WE'D RECOMMEND IS STEP BACK AND LOOK AT IT BROADLY. WE'RE FOCUSSED ON WHILE IT'S IMPORTANT [INDISCERNIBLE]. DNA AND RNA COLLECTION ARE ALL THINGS ROLLED UP. >> IT'S A VERY RICH DISCUSSION. WE THANK YOU ALL AND THANK TO THE WORKING GROUP FOR THEIR INPUT AND WE'LL KEEP YOU POSTED. WE'LL GIVE YOU PERIODIC UPDATES AND AS WE'RE ABLE TO COLLECT DATA ON APPLICATION TRENDS, THINGS OF THAT NATURE, WE'LL DO SO BUT THAT WILL BE A LAG. WE'LL TAKE A BREAK NOW FOR I THINK 15 MINUTES SO IF YOU CAN COME BACK AT 10:15 NOW WE'LL START CONCEPT CLEARANCES AS I'M SURE YOU KNOW ONE OF THE FUNCTIONS OF COUNCIL IS WHEN AN INSTITUTE OR CENTER WANTS TO START A NEW PROGRAM OR RE-ISSUE AN EXISTING PROGRAM WE COME TO YOU FOR ADVICE AND CONCURRENCE ON DOING THAT. WE'RE GOING TO HAVE A SERIES OF THOSE TODAY. AND SOME ARE KNEW OR HAVE SIGNIFICANT CHANGES TO THEM. OTHERS ARE RE-ISSUES WITHOUT SIGNIFICANT CHANGES. WE'LL START WITH PROGRAMS WITHOUT SIGNIFICANT CHANGES. I'LL GO THROUGH THOSE QUICKLY AND ASK FOR COMMENTS YOU HAVE THEN WE CAN DO A VOTE ON EACH ONE. ERICA WILL CALL FOR AN INDIVIDUAL VOTE AFTER EACH AND NEXT IS THE SCIENTIFIC PARTNERSHIP AWARDS. IT SUPPORTS PRE-KINDERGARTEN TO GRADE 12 TO ENHANCE THE BIOMEDICAL WORKFORCE AND FOSTER A BETTER UNDERSTANDING OF NIH FUNDED RESEARCH AND PUBLIC HEALTH IMPLICATIONS. WE WANT TO RE-ISSUE THIS. TONY IS IN THE BACK IS THE PRIMARY PROGRAM OFFICER AND THIS WILL HAVE NO SUBSTITUTIVE CHANGES. THERE WAS AN EVALUATION COMPLETED OF SEPA AND CHANGES WERE MADE IN RESPONSE TO THAT. IT IS IN THE DIVISION OF RESEARCH CAPACITY BUILDING WHERE YOU MAY REMEMBER IT MOVED A COUPLE YEARS AGO FROM THE OFFICE OF THE DIRECTOR SO WE ACTUALLY ACQUIRED IT THANKS TO CONGRESS. >> DO I HAVE A MOTION TO APPROVE THE CONCEPT? SECOND, ALL APPROVED, ANY OPPOSED? THE SECOND IS RELATED THE SECOND IS THE PROGRAM FOR INTERACTIVE DIGITAL MEDIA. THE PURPOSE IS TO GIVE GRANTS TO SMALL BUSINESSES AND TRANSFER GRANTS BETWEEN ACADEMIC BUSINESS TO CREATE MEDIA PRODUCT TO PROMOTE STEM EDUCATION AND FOSTER AN UNDERSTANDING OF CAREERS IN HEALTH AND MEDICINE, BIOMEDICAL RESEARCH FIELD. THE PROGRAM HAS BEEN SUCCESSFUL AND THERE'S AN EVALUATION AND WE HAVE THE PROGRAM DIRECTOR. ARE THERE ANY COMMENTS OR QUESTIONS ABOUT THAT? >> IF NOT DO I HAVE A MOTION TO APPROVE THE CONCEPT. SECOND? ALL APPROVED? ANY OPPOSED? >> THANK YOU. THE SECOND WE STARTED WITH GUIDANCE FROM YOU THE COLLABORATIVE PROGRAM GRANT FOR MULTIDISCIPLINARY TEAMS USING THE RM1 ACTIVITY CODE. THEY SUPPORT A SINGLE HIGH-IMPACT WELL INTEGRATED PROJECT AND TEAM SCIENCE PROJECT THAT IS OF LARGE SCOPE AND COMPLEXITY SUCH THAT IT CAN'T BE ACCOMPLISHED THROUGH MULTIPLE P.I.s AND COLLABORATING TOGETHER IN AN EASY WAY AND WE HAD ONE SIGNIFICANT CHANGE IN THE VERSION OF THE DEFINITION OF CLINICAL TRIALS WAS GOING ON WE DIDN'T ACTUALLY STATE CLINICAL TRIALS WERE ALLOWED. THE NEW DEFINITION OF CLINICAL TRIALS ENCOMPASSES THINGS THAT PREVIOUSLY MAY NOT HAVE BEEN THOUGHT OF AS A TRADITIONAL CLINICAL TRIAL. ANY INTERVENTION IN HUMAN WITH A RESEARCH OUTCOME IS A CLINICAL TRIAL. TO MAKE THIS CLEAR AND WATER TIGHT, WE WANT TO ADD NIHs DEFINITION OF CLINICAL TRIAL TO THE FOA SO SOMEBODY DOING RESEARCH IN SEPSIS WHERE THEY'RE DOING A RESEARCH INTERVENTION IN A PERSON COULD APPLY. WE'RE ADDING BOILER PLATE LANGUAGE TO MAKE THAT CLEAR AND POSSIBLE. THE EVALUATION HASN'T BEEN DONE BECAUSE THE FIRST AWARDS WERE DONE THIS YEAR SO THERE'S NOT MUCH TO EVALUATE. THROUGH THE INSTITUTE AND PETER DRUSH IS LEADING THE EFFORT. ANY CONCERNS ABOUT THE ONE CHANGE WE'RE MAKE >> DO I HAVE A MOTION TO APPROVE THE CONCEPT? >> DO I HAVE A MOTION. A SECOND? ANY OPPOSED? >> WE'LL SEE HOW IT GOES AS WE CONTINUE ALONG WITH IT. THAT IS THE CONCEPT CLEARANCES THAT WE'RE DOING FOR RE-ISHANCES. NOW TO GO MORE IN DEPTH ON THE REISSUANCES FOR THE EARLY STAGE INVESTOR MIRA PROGRAM I TOLD YOU A LITTLE BIT ABOUT BEFORE. I SHOWED YOU THE DATA ON THE INCREASING POPULATION -- POPULARITY OF THE PROGRAM AND 70% WILL COME THROUGH THIS PROGRAM AND ONE MORE RECEIPT DATE IN THE CURRENT FOA BUT WE NEED TO RE-ISSUE THIS TO CONTINUE THE PROGRAM. SO THE FIRST ONE WAS ISSUED IN 2015 WITH FUNDING IN 2016. WE ISSUED IT A COUPLE MORE TIMES SINCE THEN. THERE WERE 93 TOTAL AWARDS MADE IN 2016. I SHOULD HAVE MENTION THE E.S.I. ON THE SLIDES WERE JUST E. SIXT S.I. AND WE HAD NEW INVESTIGATORS AVAILABLE TO APPLY BUT FOR REASONS IT WAS COMPLICATED IN TERMS OF DECIDING WHO WAS REALLY APPROPRIATE WE FOCUSSED AND SAID EARLY STAGE INVESTIGATORS AND SUBSEQUENT FOAs. 2018, 112 THROUGH THE PROGRAM. THOSE ARE THE SUCCESS RATES IN PARENTHESES ARE HIGH. THE SUCCESS RATES ARE HIGH, 30% AND ABOVE. I THINK THIS YEAR WE'LL GET CLOSE TO 40%. OVERALL A 31.4% WHICH IS HIGHER AND THE SUCCESS RATE IS BY 26%. AND ONE IMPRESSIVE THING WE WERE SURPRISED BY WASN'T INTENTIONAL BUT WE'VE BEEN PLEASED BY IS THE MEAN AGE OF PEOPLE GETTING THEIR E.S.I. MIRA'S FIRST MAJOR GRANT IS YOUNGER THAN THOSE WHO GET THEIR FIRST GRANT THROUGH NIGMS AS AN RO1. IT'S 37 FOR A MIRA AND 38.5 OR SO FOR AN RO1. >> JOHN, TO WHAT DO YOU ATTRIBUTE THE HIGHER SUCCESS RATE? >> INSTITUTIONAL PRIORITIES. THE MIRA PROGRAM IS A PRIORITY AND E.S.I.s SAY PROGRAM AND MORE PEOPLE ARE APPLYING THROUGH THE MIRA PROGRAM. THAT'S PART OF IT. AND WE'RE FUNDING PEOPLE EARLIER AND SO BOTH THINGS ARE TRUE. WE'VE MADE A STRATEGIC PRIORITY OF THE INSTITUTE TO BRING THAT AGE DOWN FURTHER. I TOLD THE SENATE APPROPRIATION SUBCOMMITTEE THAT WE WANTED TO GET THAT AGE DOWN TO 35. AND WE'RE GETTING PEOPLE TO APPLY ONCE THEY GET TO THE INSTITUTION AND ENSURE THAT IN REVIEW, REVIEWERS ARE UNDERSTANDING THAT'S WHAT WE'RE LOOKING FOR AND NOT EXPECTING PEOPLE TO HAVE PUBLICATIONS FROM THEIR INDEPENDENT WORK WHEN THEY APPLY WHICH IS OFTEN THE CASE WITH RO1s. WE WANT TO ENCOURAGE EARLY STAGE INVESTIGATOR TO APPLY AS SOON AS THEY'RE INDEPENDENT FACULTY MEMBERS WHICH IS HOW IT USED TO BE A LONG TIME AGO WITH RO1s AND THERE'S BEEN A SHIFT OVER THE YEARS. THEREFORE, WE WILL URGE REVIEWERS IN THE FOA TO CONSIDER SCIENTIFIC PROMISE RATHER THAN DEMONSTRATIONS OF THEIR PUBLICATIONS OR PRELIMINARY DATA FROM THEIR INDEPENDENT JOB AND WANT TO GET THEM TO MOVE TO RESEARCH AREAS DISTINCT FROM THEIR POST-DOCTORAL MENTORS. IN BIOLOGICAL BIOLOGICAL SCIENCE ISN'T WHA T NORMALLY HAPPENS. WE'D LIKE TO MOVE AT LEAST ALLOW PEOPLE TO BE MORE BOLD AND MORE FREE INTO MOVING TO NOW TERRITORIES RATHER THAN BE CONSTRAINED AS A POST-DOC. WE THINK IT SHOULD FREE UP AND EXPLORE NEW TERRITORIES AND MAKE DISCOVERIES FASTER. THAT'S SOMETHING WE'LL TRY TO MAKE CLEAR IN THE FOA AGAIN AND TELL REVIEWERS WE DON'T EXPECT APPLICANTS THEY'LL PROPOSE ON SOMETHING THEY DID AS A POST-DOC SQUIRE. >> SO KIND OF CRITERIA WILL YOU TELL REVIEWERS TO USE IN MAKING THEIR DECISION. WHAT CRITERIA ARE WE LOOKING FOR? >> SIMILAR MIND SET TO WHEN YOU HIRE SOMEBODY. YOU LOOK AT WHAT THEY DID AS A GRAD STUDENT, POST-DOC, IDEAS PROPOSED FOR MOVING FORWARD. THERE'S NO -- >> Reporter: IS THAT DISADVANTAGED PEOPLE NOT TOP 10 SCHOOLS. >> THAT'S A CONCERN LOOKING TOO MCH AT PEDIGREE AND MAY BE SOMETHING WE WANT TO STRESS. I THINK IT'S A GREAT POINT. HOWEVER WE'RE NOT SEEING THAT. WE'RE SEEING A BROADENING OF THE SCHOOLS. IT MAY BE FREEING THINGS UP AND IS LEADING REVIEWERS TO BE BROADER IN THEIR THINK AND IF WE CAN KEEP THE SUCCESS RATE HIGH IT ALLOWS A BIGGER WINDOW OF PROMISING INVESTIGATORS. IF WE CAN KEEP IT AROUND 40%, HIGH 30%s THAT WOULD BE -- >> THE SUCCESS RATE INCLUDES THE NUMBER OF TIMES YOU SUBMIT AS WELL. YOU GOT A 40% CHANCE OF GETTING IT. >> WHAT'S THE TRUTH BECAUSE YOU DON'T HAVE TIME TO SUBMIT ANOTHER ONE THE SAME YEAR BECAUSE OF THE WAY THE CYCLE WORKS. WE'RE FUNDING 40% OF THE ONES THAT COME IN THIS YEAR. I THINK THOSE ARE EXCELLENT POINTS WE SHOULD MAYBE EMPHASIZE THE NEED AROUND THAT. I THINK THOSE POINTS THAT YOU MADE ARE GOOD. ENRIQUE. >> I WAS GOING ASK ABOUT THE DISTRIBUTION AND POST-DOCTORAL FELLOWSHIPS YOU SEE A HIGH DENSITY ON IN CERTAIN PLACES. LET ME ASK A DIFFERENT QUESTION THEN, ARE YOU SEEING A BIAS OR GREATER FRACTION OF PEOPLE THAT ARE IN INSTITUTIONS WITH FACULTY VEIL SUPPORT. >> -- SALARY SUPPORT. >> WE HAVEN'T SIGNIFICANTLY LOOKED AT THAT BUT LOOKING AT THE DATA IT SEEMS IT TILTS TOWARDS INSTITUTIONS THAT ARE NOT SOFT MONEY. MY HOPE TO SOME EXTENT IS BY MOVING MORE AND MORE IN THIS DIRECTION WE'LL PUT PRESSURE ON THOSE INSTITUTIONS TO FIND WAYS TO SUPPORT THEIR FACULTY SALARIES. I DON'T THINK IT'S BENEFICIAL FOR THE RESEARCH ENTERPRISE. >> IT'S NOT LOOKING FOR THE MOST INTERESTING NEW AREA OF RESEARCH. YOU MAY LOOK AT THE PIPELINE OF THAT. >> I WANT TO MAKE SURE I CLEARLY UNDERSTAND TO INFORM COLLEAGUES. THE MIRA HAVE A HIGHER CHANCES OF BEING FUND THAN AN RO1 FROM AN EARLY STAGE INVESTIGATOR BECAUSE IT'S AN NIGMS PRIORITY. IF SOMEBODY SMITS AN RO1 AND GETS AN CERTAIN SCORE AND THERE'S A GREATER CHANCE OF THE SCORES. >> WE LOOK AT EVERY GRANT AND EVERY APPLICATION AND ALL THE PARAMETERS ASSOCIATED WITH IT. THE SCORE, THE SUMMARY STATEMENT, THE INDIVIDUAL REVIEWS. OTHER SUPPORT PEOPLE HAVE. THE AREA THEY'RE WORKING IN. THE OTHER FACTOR IS 50 APPLICATIONS WE HAVE A BIG PORTFOLIO IN, THAT MAY NOT BE AS HIGH OF A PRIORITY AND THE ONE IS IN THE DARK MATTER OF SCIENCE SOMEBODY TALKED ABOUT BEFORE. IT'S HARD TO EXACTLY ANSWER YOUR QUESTION BECAUSE EACH CASE IS LOOKED AT INDEPENDENTLY AND THE HIGHER SCORES IS STILL MERITORIOUS. AND WE PROBABLY FAVORED MIRA OVER RO1s. TO SAY TWO THINGS, AT THIS STAGE IF YOU'RE ADVISING JUNIOR COLLEAGUES THERE'S VERY LITTLE DOWNSIDE AND A LOT OF UPSIDE TO GETTING A MIRA INSTEAD OF RO1. THE OWN REASONABLE YOU MAY WANT AN RO1 IS IF YOU THINK YOU'LL GET MORE THAN ONE FROM US. THE DATA SAY AND WE'RE INCREASINGLY PUTTING PRESSURE ON PEOPLE GETTING MULTIPLE RO1 AND THE OTHER IS IF YOUR RESEARCH DOESN'T FIT IN THE MIRA PARADIGM. WE'LL SEE THIS IS SOMEONE WHOSE RESEARCH IS FOCUSSED EXCLUSIVELY ON TECHNOLOGY DEVELOPMENT MOVING THINGS WITH MILESTONES THROUGH A PIPELINE. MAYBE THEY'RE DOING CLINICAL TRIALS AND THE MIRA IS NOT AS GOOD MECHANISM. >> HAVE YOU THOUGHT OF HOW YOU'LL DO ANALYSIS AND LOOK AT AND HOW K99 AWARDEES TRANSITION. ARE THEY MORE ADEPT AT TRANSITIONTION O TRANSITIONTION -- TRANSITIONING TO A MIRA. >> THE NUMBERS HAVE TO BE BIG ENOUGH TO MAKE THOSE KINDS OF CORRELATIONS IF THE EFFECT SIZES ARE SMALL. WE WANT THE SUCCESS RATE FOR RENEWALS BE HIGH. CAN'T GIVE AN EXACT NUMBER BECAUSE IT DEPENDS ON A LOT OF DIFFERENT FACTORS BUT WE WANT IT TO BE HIGH. PEOPLE ARE NOT CAPPED AT $450,000 SO THEY'RE DOING BETTER OFF THAT BUT SOME RESEARCH PROGRAMS GOING GREAT GUNS. IT MAKE SENSE FOR THEM TO ADD MORE POST-DOCS AND BRINGING IN NEW TECHNOLOGIES, THEY SHOULD BE ABLE TO EXPAND THE PROGRAM. THE OTHER ISSUES AND YOU BROUGHT UP EXCELLENT POINTS WE'LL THINK OF INCORPORATING AS WELL, WE WANT TO EMPHASIZE PRELIMINARY DATA IS NOT REQUIRED OR EXPECTED. DO YOU EXPECT THEM TO HAVE KNOWN THAT IN THEIR LAB AND WE WANT TO GET PEOPLE FUNDED EARLY AND GIVE THEM A CHANCE WITH THEIR OWN RESEARCH PROJECT TO WORK FOR FIVE YEARS AND SEE WHAT THEY CAN ACCOMPLISH. TIME YOU FUND A GRANT IT'S A RISK. IT'S RISK ERWITH EARLY STAGE INVESTIGATOR BUT THAT'S A RISK WE HAVE TO TAKE AND THINK WE HAVE TO TAKE A LOT OF TO FIND THE BEST PEOPLE WORKING ON THE MOST DIVERSE AND INTERESTING PROBLEMS. THEY'LL BE REVIEWED IN ONE PANEL WITHOUT ESTABLISHED INVESTIGATORS BEING REVIEWED AT THE SAME TIME. TIME LINE CONCEPT CLEARANCE AND FOA TO BE ISSUED THIS SUMMER. APPLICATION RECEIPT DATES AS SHOWN, REVIEWED BY CSR AND SOMETHING LIKE THAT TIME LINE WITH THE FOLLOWING COUNCIL ROUND OF REVIEW AND IN THE EARLIEST AWARD DATES STARTING JULY, 2021. SO ARE THERE ANY QUESTIONS ABOUT THAT IN ADDITION TO WHAT WE'VE DISCUSSED? >> CAN I HAVE A MOTION TO APPROVE THE CONCEPT? SECOND? ALL IN FAVOR? ANY OPPOSED? >> THANK YOU VERY MUCH. WE'LL MOVE AHEAD AND KEEP YOU POSTED. SO NEXT WE'LL HAVE A SWAN SONG BREAKING MY HEART. FROM SUSAN. WE COUNCILED HER FOR BBT ACTIVITIES. >> THANK YOU FOR ALLOWING ME TO COME BACK FOR AN ENCORE PERFORMANCE. >> ALLOWING? BEGGING. >> THIS IS A WONDERFUL INSTITUTE IF YOU'RE LOOKING TO MAKE SIGNIFICANT CHANGE AND IMPACT IN BASIC RESEARCH YOU CAN'T WISH FOR A PARTICULAR HOME AND WANT TO THANK YOU AND MY MENTOR AND NOW I WANT TO COMPLETE MY GOAL OF THINKING ABOUT BIOMEDICAL TECHNOLOGY. I'M GOING PRESENT A CONCEPT CLEARANCE THAT'S REISSUING OF AN EXISTING PROGRAM YOU MAY KNOW OF THE BIOMEDICAL TECHNOLOGY RESOURCE. WE'D LIKE TO OFFER A FEW CHANGES TO THIS CHANGES INCLUDING THE TITLE AND THE TITLE SAYS IT ALL. IT'S A PIVOT TO BIOMEDICAL TECHNOLOGY DEVELOPMENT AND DISSEMINATION CENTERS. I WANT TO THANK MY COUNCIL REVIEWERS, CATHY AND MIKE, FOR HELPING FORMULATE THIS NEW FOA. I THINK I NEED IT GIVE YOU PERSPECTIVE AND BACKGROUND ON BIOMEDICAL TECHNOLOGY DEVELOPMENT. IT'S THE PIPELINE IN WAYS IN WHICH RESEARCHERS CAN THINK ABOUT AND DEVELOP TECHNOLOGY. DOWN HERE YOU'LL SEE THE CORRESPONDING F.Y.s. IT'S NOT A P.I. PIPELINE BUT TECHNOLOGY AND THINK ABOUT EXPLORE RESEARCH AND TECHNOLOGY FEASIBILITY. HAVE YOU AN I'D YEAH, A CONCEPT. DON'T HAVE PRELIMINARY DATA AND WANT TO GET IT TO A PROTOTYPE STAGE. THAT'S THE GOAL OF THIS PROGRAM THE R21. NO PRELIMINARY DATA ALLOWED I HAVE TO STRESS THAT AND THE SECOND IS THIS IS NOT AN E.S.I. STARTER GRANT. THERE'S MANY GOOD PROGRAMS AT NIGMS FOR E.S.I. APPLICANTS. THIS FOR PEOPLE WANT TO TAKE CONCEPT AND DEVELOP IT TO A PROTOTYPE. THERE'S WAYS TO TAKE IT AND FURTHER IT RATE ON THE DEVELOPMENT. THIS SAY RESEARCH IDEAS WHERE YOU FOCUS YOUR TECHNOLOGY DEVELOPMENT AND A MECHANISM FOR RO1 GRANTEES. YOU HAVE TO SHOW THE CONCEPT IS FEASIBLE AND COULD WORK AND YOU'RE GOING TO DO RESEARCH TO GET TO THAT STAGE. AND THIS IS NOT NECESSARILY A RESEARCH PROGRAM. IT'S TO DEVELOP THE TECHNOLOGY TO THE STAGE WHERE OTHER PEOPLE CAN USE IT EITHER YOU'LL DISSEMINATE IT TO RESEARCHERS IN THE LABS OR COMMERCIALIZE IT BUT YOU WANT TO DEVELOP AND DISSEMINATE THE TECHNOLOGY. THIS IS WHAT WE'RE FOCUSSING ON TODAY AND THE OLD PROGRAM THE BIOMEDICAL TECHNOLOGY DEVELOPMENT RESOURCES BUT WE'RE RETHINKING THAT AFTERWARDS. THERE'S MANY PATHWAYS. YOU COULD HAVE A MATURE TECHNOLOGY AND WANT TO ENGAGE MANY USERS ON A NATIONAL AND REGIONAL SCALE. OR WOULD LIKE TO COMMERCIALIZE IT OR GONE THROUGH THE DISSEMINATION STAGE AND CAME UP WITH NEW IDEAS. WHY NOT APPLY FOR A NEW RO1 TO DEVELOP IT OR IF IT'S A NOVEL IDEA THINK OF AN R21. THESE THE DIFFERENT STAGES. TODAY I'M TALKING ABOUT THE BIOMEDICAL TECHNOLOGY P41 PROGRAM. IT'S BEEN IN EXISTENCE FOR 51 YEARS AND EVALUATED IN 2015. THE MISSION IS TO DEVELOP AND DISSEMINATE CUTTING EDGE TOOLS AND ENVIRONMENTS TO ADVANCE BASIC BIOMEDICAL RESEARCH. THE ANNUAL BUDGET IS $66 MILLION AND THERE'S 31ETRR CENTERS. WE HAVE DONE SOME CHANGES IN THE LAST REISSUANCE BASED ON THE COMMENTS FROM COMMUNITY AND COUNCIL. WE EMPHASIZE A SHIFT FROM RESOURCE ACCESS TO TECHNOLOGY DISSEMINATION. YOU HAVE TO COMPLETE THE DISSEMINATION WITHIN A 15-YEAR PERIOD AND MOVED THE SYNCERTRON RESOURCE. OUR APPLICANT POOL IS REVIEWED AND EVALUATED IN A SET PANEL AND WE PLACING THE PREVIOUS SITE VISITS WE USED TO DO AND THINK IT'S BEEN POSITIVE FOR THE COMMUNITY AS A WHOLE AND ARE PLEASED WITH WHAT WE'VE BEEN ABLE TO ACCOMPLISH IN THE PAST FEW YEARS. NOW I WANT TO THINK ABOUT WHAT TO DO NOW. HERE, WE'D LIKE TO FOCUS ON THE TECHNOLOGY DEVELOPMENT AND DISSEMINATION IN THE ON RESEARCH. SO WE WOULD LIKE IT SEE STRONG PROOF OF CONCEPTS REQUIRED FOR OUR TECHNOLOGY DEVELOPMENT PROJECTS. SO EARLY STAGE RO1 AND R21 WOULD BE EXCLUDED FROM AN P41 AND SUCCESSFUL R21s CAN BE FEEDER PROJECTS INTO THE PROGRAM. THERE'S TWO BIG CHANGES HERE. WE WOULD LIKE TO ENCOURAGE MULTI-INVESTIGATOR 1R06 RO1s FOR PEOPLE TO COME TOGETHER AND FORMULATE IDEAS AND MOF ON ON -- MOVE ON IF THEY WISH AND WANT TO ENCOURAGE INVESTIGATOR MEETING WITH APPLICATIONS TO THINK ABOUT DISSEMINATION AND COMMERCIALIZATION. BRIDGING TOGETHER TECHNOLOGY P.I.s WITH COMMERCIALIZATION HUBS. WE'LL MAINTAIN THE APPLICATION WITH THE REVIEW. WE ANTICIPATE FIVE TO EIGHT COMPETING AWARDS A YEAR. A BIG CHANGE IS THE LATER STAGE TECHNOLOGY PROJECTS WILL ACT AS TEST BEDS. THEY'LL BE SUPPORTED IN THE PROGRAM. THIS FOCUS AND FOCUSES ON TECHNOLOGY AND DISSEMINATION. UNDER THE FOA, APPLICANTS ARE ELIGIBLE FOR SUPPORT FOR THEIR WORK IN THIS PROGRAM. THAT MEANS YOU CAN RECEIVE ADDITIONAL FUND IF YOU'RE AN APPLICANT. BUDGETS ARE $850,000. WE HAVE COSTS PER YEAR AND WE WOULD SUPPORT EQUIPMENT IF REVIEWED APPROPRIATELY. WE'RE LOOKING AT GENETIC TOOLS AND EMPHASIZE IN DISSEMINATION. THIS SLIDE SUMMARIZES THE EXISTING PROGRAM KNOWN AS THE BIOMEDICAL TECHNOLOGY RESOURCES AND THE PROPOSED NEW PROGRAM BIOMEDICAL TECHNOLOGY AND DISSEMINATION CENTERS. I'LL LET YOU DIGEST IT FOR A MOMENT. I DO BELIEVE THIS IS NEARLY THE LAST SLIDES AND THERE'S COMMUNITY ENGAGEMENT. AT THE STRUCTURE OF THE APPLICATION HAS NOT CHANGED AT ALL IN FACT SOME THINGS ARE THE SAME BETWEEN THE TWO PROGRAMS AND SOME THINGS HAVE CHANGED. THE LAST SLIDE IS THE TIME LINE WHEN WE EXPECT TO ROLL IT OUT. I'M HAPPY TO ADDRESS ADDITIONAL QUESTIONS. >> QUESTION OR COMMENTS. CHERYL? >> COULD YOU ELABORATE ON HOW THE APPLICANTS WOULD GET FUNDED IN THIS MECHANISM. THEY MAY BE DEVELOP PARTICULAR TECHNOLOGY, MAYBE AN IMAGING TECHNOLOGY. THAT'S THEIR RESEARCH IN THEIR MIRA PROGRAM. IN THE PROJECT THEY ARE WORKING WITH THE BIOMEDICAL PROJECTS THAT'S HARDENING OF THE TECHNOLOGY AND GETTING IT OUT THERE SO THEN THEIR APPLICATION THEY COULD HAVE A BUDGET FOR THAT PARTICULAR DISSEMINATION AND DEVELOPMENT. >> HOW ARE YOU GOING TO GAUGE SUCCESS UP TO THE 15 YEARS. I ASK BECAUSE I WONDER IS 15 ENOUGH. >> THAT'S A GREAT QUESTION. THE THINGS THAT WE LOOK AT ARE PUBLICATIONS BUT ALSO PEOPLE WHO ARE CITING AND USING THAT TECHNOLOGY AFTER 15 YEARS AND WE CAN ACTUALLY TRACK THAT THROUGH THE BIOMEDICAL PROJECTS AND ARE PEOPLE APPLYING FOR IP AND DISSEMINATING THEIR TECHNOLOGY AND PARTNERING WITH COMMERCIAL ENTITIES? ARE THEY TRAINING AND ENGAGING? COMMUNITY OUTREACH IS A VERY IMPORTANT COMPONENT OF ARE THEY TRAINING AND ENGAGING RESEARCHERS. WE LOOK AT THOSE METRICS IN ORDER TO GAUGE SUCCESS. WE FEEL IN THE SPAN OF A 15-YEAR LIFE CYCLE A P.I. SHOULD BE ABLE TO TAKE THAT TECHNOLOGY TO AN END POINT BE IT COMMERCIALIZATION OR REGIONAL OR NATIONAL RESOURCE OR BACK TO THE NEW RO1. WE SHOULD SEE A PROGRESSION OF TECHNOLOGY. >> DO I HAVE A MOTION TO APPROVE THE CONCEPT? SECOND? ALL IN FAVOR? ANY OPPOSED? >> THANK YOU VERY MUCH. WE'RE NOW GOING TO MOVE ON TO RAFI TO TALK ABOUT THE NEW FOA FOR CLINICAL AND TRANSLATIONAL RESEARCH AWARDS WITHIN THE IDEA PROGRAM. >> GOOD MORNING AND THANK YOU NOR OPPORTUNITY. TH DIVISION FOR RESEARCH CAPACITY BUILDING IS SEEKING APPROVAL FOR US TO RE-ISSUE THE FUNDING OPPORTUNITY ANNOUNCEMENT FOR OUR INITIATIVE CALLED THE IDEA PROGRAM INFRASTRUCTURE FOR CLINICAL AND TRANSLATIONAL RESEARCH OR IDEA CPR IN SHORT. IDEA IDEA CTR ARE MULTICOMPONENT AWARDS THAT SUPPORT CLINICAL AND TRANSLATIONAL RESEARCH EFFORTS IN IDEA SPACE. FOR THOSE NOT FAMILIAR WITH THE IDEA PROGRAM, IDEA STANDS FOR INSTITUTIONAL DEVELOP AWARD. IT'S A CONGRESSIONAL RESEARCH AWARD. AND CURRENTLY THERE ARE 23 STATES AND PUERTO RICO ELIGIBLE FOR IDEA PROGRAM FUNDING. IT'S THE YOUNGEST OF THE INITIATIVES WITHIN THE IDEA PROGRAM. AS THE NAME OF THE PROGRAM IMPLIES, IT'S MAIN OBJECTIVE IS TO SUPPORT THE DEVELOPMENT OF INFRASTRUCTURE AND HUMAN RESOURCES REQUIRED TO CONDUCT CLINICAL RESEARCH IN THE ELIGIBLE STATES. IT'S EXPECTED THIS AWARD WILL ENHANCE THE ABILITY OF INSTITUTIONS AND INVESTIGATORS IN IDEA STATES TO DEVELOP COMPETITIVE CLINICAL AND TRANSLATIONAL RESEARCH PROGRAMS AND THAT THE AWARDS WILL FOSTER AND SUSTAIN COLLABORATION AND COORDINATION OF CLINICAL AND TRANSLATIONAL ACTIVITIES WITHIN OR AMONG THE DIFFERENT INSTITUTIONS OR ORGANIZATIONS WITHIN THE IDEA STATES. NOW, MANY OF THE IDEA STATES ARE ALSO RURAL AND ARE ECONOMICALLY DISADVANTAGED AND GRAPPLING WITH SOME OF THE MOST PROMINENT HEALTH CONCERNS THAT WE HEAR ABOUT IN THE NEWS ALMOST EVERY DAY OBESITY AND OPIOID EPIDEMICS COME TO MIND. ANOTHER IMPORTANT OBJECTIVE OF THIS INITIATIVE IS FOR THE AWARD TO START ADDRESSING THE HEALTH CONCERNS PREVALENT IN THESE JURISDICTIONS. IMPORTANT FEATURES INCLUDE THE FOLLOWING. WE ONLY MAKE ONE IDEA CTR AWARD FOR ONE IDEA STATE. IT'S EXPECTED THIS AT THE MINIMUM STATEWIDE RESOURCES FOR LEAD INSTITUTION PARTNERS OR COLLABORATES WITH INSTITUTION OR ORGANIZATION WITHIN THE STATE OF FUNDING WHETHER THEY WANT TO ADDRESS REGIONAL HEALTH CONCERNS. THEY'RE ALLOWED TO BE ABLE TO PARTNER WITH INSTITUTIONS OR ORGANIZATIONS WIN ANOTHER IDEA STATE. NOW, INSTITUTIONS THAT CURRENTLY HOLD ANOTHER NIH FUNDED CLINICAL AND TRANSLATIONAL RESEARCH AWARD SUCH AS THE CLINICAL AND TRANSLATIONAL SCIENCE AWARDS THAT ARE FUNDED BY THE NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE OR NCATS. THOSE INSTITUTIONS MAY NOT HAVE AN IDEA CPR AWARD. -- CTR AWARD. THESE ARE MULTICOMPONENT AWARDS WHICH REQUIRE ADDITIONAL ACTIVITIES. THIS USES THE COOPERATE AGREEMENT MECHANISM WHERE THERE'S MORE SIGNIFICANT PROGRAMMATIC AWARDS AND THEY'RE CAPPED AT $4 MILLION TOTAL COST AND THIS AWARD RUN FOR FIVE YEARS AND ARE RENEWABLE. THIS IS THE CURRENT LANDSCAPE OF THE INITIATIVE. WE CURRENTLY HAVE 11 OF THE AWARDS SHOWN WITH THE STARS FOR THE LEAD INSTITUTIONS ARE LOCATED. AND EMANATE FROM THOSE STARS ARE BROKEN LINES WHICH INDICATE OR REPRESENT THE PARTNERS IN EACH OF THE NETWORKS. SO THERE ARE SOME AND THERE'S SOME IN THE RED CIRCLES. THE RED SCIRCLES RIN IDEA STATES AND THE GREEN CIRCLES ARE IN NON-IDEA STATES. THERE'S NOTABLE OBSERVATIONS. YOU PROBABLY NOTED ALREADY ONE NOTABLE OBSERVATION IS THE VARIANCE OR DIVERSITY IN THE OUTREACH OF THE AWARDS. MOST OF THE IDEA CTR AWARDS INVOLVE A PARTNERSHIP BETWEEN TWO OR THREE STATES. THE GEOGRAPHICAL COVERAGE AND INSTITUTIONS IN THE AWARDS SPAN THE SPECTRUM. WE HAVE A SITUATION, FOR INSTANCE IN RHODE ISLAND WHICH IS STRICTLY A STATEWIDE NETWORK. ON THE OTHER END OF THE SPECTRUM IS A SITUATION IN THE WEST WHERE WE HAVE A CTR LED BY UNLV PARTNERING WITH SP -- 13 INSTITUTIONS COVERING SEVEN STATES. THAT'S A THIRD OF ALL THE IDEA STATES. GIVEN THE FINITE RESOURCES THAT ARE PROVIDED BY THE PROGRAM FOR THESE PROGRAMS, THE NUMBER OF PARTNERS AND THE GEOGRAPHICAL COVERAGE HAS IMPLICATIONS HOW FAR THE RESOURCES CAN GO IN MAKING A SIGNIFICANT IMPACT IN THIS DIFFERENT INSTITUTIONS COVERED. YOU MAY ALSO HAVE NOTED THERE ARE CERTAIN AWARDS THAT OVERLAP IN COVERAGE. THAT COMES BECAUSE OF THE VARIANCE AND SCOPE OR FOCUS OF THIS CTR AWARDS. SO THAT'S THE SECOND NOTABLE OBSERVATIONS AMONG THESE AWARDS. SO THERE IS EYE DIVERSITY IN THE FOCUS OR SCOPE OF THIS AWARD WITH SOME OR MOST OF THE IDEA CTR AWARDS FOCUS ON THE BROAD HEALTH CONCERNS THAT CAN BE SEEN IN THIS JURISDICTIONS WHEREAS THERE ARE SOME AWARDS WHICH ARE VERY NARROW IN THEIR SCOPE EITHER IN THE DISEASE THEY FOCUS OR IN THE POPULATION THEY COVER. FINALLY, ONE OTHER ONE OTHER NOTABLE OBSERVATION IS THE ALLIANCE BETWEEN CTRs AND CTSAs. YOU CAN SEE THERE'S A NUMBER OF THEM ALMOST ALL OF THEM EXCEPT FOR A FEW CASES WHERE THEY PARTNER WITH WITHIN THE STATE OR OUTSIDE. MOST ALLIANCES ARE COME IN THE FORM OF LEVERAGING OF EDUCATIONAL MENTORS AND RESOURCES ALREADY IN PLACE BY THE PARTNERS. THERE ARE A FEW HOWEVER WHERE THE PARTNERSHIP IS INVOLVED I MUCH MORE SIGNIFICANT RELATIONSHIP WHERE IN FACT SOME OF THE COURSE ARE LOCATED IN THE CTSA INSTITUTIONS. SO IN LIGHT OF THIS NOTABLE OBSERVATIONS, WE HOPE TO ISSUE THE FUNDING OPPORTUNITY ANNOUNCEMENT FOR THIS INITIATIVE WITH THE FOLLOWING PROGRAMMATIC I'MS THAT NEED TO BE -- ITEMS THAT NEED TO BE EMPHASIZED. THIS INITIATIVE IS INTENDED TO SUPPORT STATE-WIDE OR MULTI-STATE INFRASTRUCTURES AND EACH AWARD ADDRESS THE BROAD SPECTRUM OF HEALTH CHALLENGES FACED WITH THE POPULATION IN THE DIFFERENT JURISDICTIONS. IT'S IMPORTANT TO KNOW WE ALREADY HAVE ANOTHER MECHANISM WITHIN THAT IDEA PROGRAM THAT WAS MENTIONED EARLIER. IT STANDS FOR CENTERS OF BIOMEDICAL RESEARCH EXCELLENCE. IT'S A MECHANISM THAT SUPPORTS MULTIDISCIPLINARY FOCUS AROUND THE SIMPLE SCIENTIFIC AREA. SO IF THERE ARE APPLICANTS INTERESTE IN LOOKING AT SPECIFIC DISEASE OR SPECIFIC POPULATION THEY CAN AVAIL OF THAT PROGRAM. A SECOND IMPORTANT THING WE NEED TO EMPHASIZE IS THE PARTNERSHIPS THAT HAVE TO BE OPTIMIZED TO MAKE SURE THEY IMPACT THE RESOURCES ARE MAXIMIZED. THEY HAVE TO INFORM THOSE PARTNERSHIPS. LASTLY, WE NEED TO EMPHASIZE THE AWARDS THEY SHOULD LEVERAGE AND NOT DUPLICATE OR COMPETE WITH THE CLINICAL AND TRANSLATIONAL CAPACITY BUILDING EFFORTS ALREADY DEVELOPED BY THE CTSA PROGRAM IN THE IDEA SPACE. IF WE GET COUNCIL APPROVAL WE PUBLIC THIS FOA BY LATE SPRING OF 2020 FOR US TO BE ABLE TO ACCEPT NEW AND RENEWABLE APPLICATIONS IN EARLY OCTOBER. THE REVIEW DATES WILL BE IN THE FIRST PART OF THE YEAR FOR COUNCIL REVIEW IN MAY AND WE HAVE THE EARLEST STAGE NOR AWARDS WILL BE -- EARLIEST STAGES AWARDS WILL BE JULY. >> DO I HAVE A MOTION TO APPROVE THE CONCEPT? SECOND? ALL IN FAVOR? ANY OPPOSED? >> ALL RIGHT. NOW WE'LL HERE FROM ALISON GAMMIE TO TALK ABOUT REISSUING THE NEW T3 FOA AND UPDATES WE'RE HOPING TO MAKE TO THAT. >> I'M HERE TO BRING YOU THE BASIC BIOMEDICAL T32 FUNDING ANNOUNCEMENT. WE ORIGINALLY LAUNCHED THIS FUNDING OPPORTUNITY ANNOUNCEMENT IN 2017. THE GOAL WAS TO TRY TO CATALYZE CHANGE IN GRADUATE EDUCATION. I'M GOING TO GO THROUGH SOME OF THE OVERARCHING THEMES FOUND IN THE FUNDING OPPORTUNITY ANNOUNCEMENT. WE HAD A STRONG EMPHASIS ON SKILLS DEVELOPMENT OF THE TRAINING. FOCUS ON TRAINING SKILL DEVELOPMENT AND WANT TO ENCOURAGE EVIDENCE-BASED APPROACHES TO PROVIDE TECHNICAL, OPERATIONAL AND PROFESSIONAL SKILLS AND YOU CAN SEE THE SPECTRUM OF SKILLS AT THE BOTTOM OF THE SLIDE METHODS IN TECHNOLOGY TO ACQUIRING INFORMATION AND EXPERIMENTAL DESIGN INTERPRETATION UP TO COMMUNICATION AND TEAM WORK. A RANGE OF SKILLS NEEDED FOR MODERN SCIENTISTS. AND WE WANT TO SEE SPECIFIC AIMS FOR THE TRAINING SO THAT OUR OBTAINABLE, MEASURABLE TRAINING OBJECTIVES GEARED TO SCIENTISTS THIS PROGRAM IS FOCUSSING ON. AND THE CONDUCT OF RESEARCH AREN'T JUST TAKEN CARE OF IN COURSES BUT THREADED THROUGHOUT THE ENTIRE TRAINING EXPERIENCE FROM THE MOMENT THE TRAINEES ENTER UNTIL THEY'RE AWARDED THEIR DEGREES. ALSO, AND ELEVATED DIVERSITY AND INCLUSION TO A SCORE REVIEW CRITERIA WE FEEL IS ESSENTIAL FOR EXCELLENCE IN RESEARCH TRAINING TO HAVE SCORED REVIEW CRITERIA AND WANT TO SEE MENTOR TRAINING OF OVERSIGHT AND MENTOR, MENTEE MATCH TO MAKE SURE ALL IS GOING WELL THROUGH THE TIME THE TRAINEE'S IN THE PROGRAM. ANOTHER NEW ELEMENT WAS TO EMPHASIZE THE IMPORTANCE OF CAREER PREPAREDNESS AND TO TRANSITION INTO THE RANGE OF CAREERS SO THEY'RE WELL EQUIPPED TO MAKE A SMOOTH TRANSITION IN THE PATHWAY. ANOTHER ELEMENT WE EMPHASIZED A GREAT DEAL IN THE FUNDING OPPORTUNITY ANNOUNCEMENT IS TO HAVE STRONG INSTITUTIONAL SUPPORT. WE HAVE A 10-PAGE LETTER THAT'S REQUIRED ENSURING THE INSTITUTION IS COMMITTED TO TRAINING EXCELLENCE AND HAS THE RESOURCES IN PLACE TO ENSURE THE SUCCESS OF THE PROGRAM AND ENSURE THAT THE TRAINEES HAVE SUPPORT THROUGHOUT THE TIME THEY'RE THERE. ANOTHER COMPONENT WE HAVE ELEVATED TO THE SCORED REVIEW CRITERIA IS TO HAVE AN EVALUATION NETWORK SET UP TO COLLECT DATA AND ALSO DISSEMINATE THEIR SUCCESSES AND FAILURES AND TRAININGS AND TO MAKE THEIR CAREER OUTCOMES PUBLICLY AVAILABLE IN SOME WAY TO ENSURE TRAINEES KNOW WHERE STUDENTS WHO HAVE NOT PASSED BEFORE HAVE ENDED UP IN THEIR CAREERS. WE HAVE SOME ATTENTION FOR THE FUNDING OPPORTUNITY ANNOUNCEMENT AND ONE EXAMPLE HERE IN THE RECENT NATIONAL ACADEMIES REPORT FOR GRADUATE STEM EDUCATION FOR THE 21st CENTURY AND SAYING THIS IS AN EXAMPLE OF A POLICY ACTION DIRECTED AT STIMULATING SIGNIFICANT CHANGE IN GRADUATE TRAINING. IT'S ALSO GOT THE ATTENTION OF NIN WIDE AND THE LANGUAGE AROUND RIGOR AND TRANSPARENCY TO ENHANCE REPRODUCIBILITY AND ASPECTS OF DIVERSITY AND INCLUSION ARE GOING TO BE INCLUDED IN THE PARENT ANNOUNCEMENT WHICH IS ENCOURAGING MEANING IT WILL HAVE A BROADER REACH THAN JUST NIGMS. AND ALSO IMPORTANTLY WE WROTE THIS A FEW YEARS BACK AND IT'S NOW SERVED AS A SEM PLATE FOR ALL OF -- TEMPLATE FOR ALL OF OUR TRAINING PROGRAMS WHICH WE'VE DONE A SIGNIFICANT RESTRUCTURING FOR OUR MEDICAL SCIENCE TRAINING PROGRAM FOR OUR DIVERSITY ENHANCING PROGRAMS AS WELL AND MUCH OF THE LANGUAGE HAS BEEN INCORPORATED THROUGHOUT THE COMMON THEMES ARE INTEGRAL TO ALL THE NIGMS PROGRAMS. ONE IS TO EMPHASIZE CURRICULUM CHANGES AND WE DID THIS IN SUBSEQUENT FOAs TO HAVE APPENDIX FOR THE REQUIRED COURSES. SO IF THERE'S A COURSE OR ACTIVITY OR INTEGRAL TO THE PROGRAM, THERE SHOULD BE A SYLLABUS OR SOME DESCRIPTION OF THIS REQUIRED ACTIVITY. THIS ALLOWS THE REVIEWERS TO DIVE DEEP AND SEE WHAT KINDS OF CURRICULAR OFFERINGS ARE THERE. WE WANT TO SEE THEY'RE TAKING A LOOK AT THE CURRICULUM AND MAKING SURE IT MATCHES WITH THE CURRENT STATE OF SCIENCE IN THAT PARTICULAR FIELD AND HAS BEEN MODERNIZED TO ADDRESS THE CURRENT NEEDS IN THE BIOMEDICAL SCIENCES. WE WANT TO STRONGLY ENCOURAGE PARTNERSHIPS AND GETTING INPUT FROM POTENTIAL EMPLOYERS INCLUDING INDIVIDUALS IN INDUSTRY, GOVERNMENT OR NONPROFIT TO ENSURE THERE IS GOOD FEEDBACK AND THE TRAINEES ARE GETTING THE SKILLS THEY NEED TO TRANSITION TO THIS RANGE OF CAREERS. WE ALSO WANT TO ENCOURAGE THE HIGHEST STANDARDS OF PRACTICE IN BIOMEDICAL RESEARCH. EXAMPLES INCLUDE RECORD KEEPING, LABORATORY NOTE BOOKS, STANDARDS OF SAFETY PARTICULARLY WHEN YOU THINK ABOUT THE DIFFERENCE BETWEEN ACADEMIA AND INDUSTRY IN TERMS OF SAFETY STANDARDS. SO WE WANT TO MAKE SURE THAT THEY ARE PLOYING THE HIGHEST -- EMPLOYING THE HIGHEST STANDARDS SO TRAINEES ARE READY TO TRANSITION TO A RANGE OF CAREERS. WE'LL ADD AN OUTCOME AND DATA STORAGE PLAN AND DISSEMINATION PLAN INTO THE ATTACHMENTS. THIS IS SOMETHING WE'VE REALIZED GIVES THE GRANTEES A PARTICULAR PLACE TO DISCUSS IN DETAIL HOW THEY'RE GOING TO HANDLE OUTCOMES AND ANALYSIS AND DATA STORAGE AND HOW THEY'LL DISSEMINATE THEIR SUCCESSES AND FAILURES. THERE IS A REQUIRED TRAINING TABLE THOSE ON PROGRAMS KNOW THE TRAINING TABLE AND IT STRIKES FEAR IN YOUR HEART. IT WAS A HUGE AMOUNT OF PERSON HOURS TO COMPLETE THIS PARTICULAR TABLE. THE REVIEWERS DID NOT FIND IT PARTICULARLY HELPFUL TO MAKE DECISIONS. THERE'S SOME IMPORTANT DATA THERE AND WE'RE GOING ASK FOR THAT IN THE TEXT BUT WE'RE NOT GOING REQUIRE THE EXTENSIVE PERSON HOURS. IT'S VERY CLEAR THAT WENT INTO GENERATING THE TABLES. WE JUST HAVE TO WORK WITH THE LANGUAGE AND TEXT TO MAKE SURE REVIEWERS HAVE INFORMATION THEY NED TO UNDERSTAND HOW MANY SLOTS TO AWARD. THAT'S THE MAIN THING THEY TEND TO GET OUT OF THE TABLE. WE HAVE TO MAKE SURE THAT'S CLEAR. THE TIME LINE IS HERE. IT'S A PRETTY STRAIGHTFORWARD TIME LINE PROVIDED YOU GRANT US APPROVAL AND THE FIRST AWARDS WILL COME OUT IN JULY 2021. SO WITH THAT I'LL TAKE ANY QUESTION OR HAVE ANY COMMENTS. >> QUESTIONS OR COMMENTS. >> THE RETIRED APPENDIX MATERIAL MAY BE CONFUSING BECAUSE THEY CLAMPED DOWN APPENDIX MATERIAL SO TIGHTLY WITH THE T32 APPLICATION OTHER THAN EVALUATION A PERSON WOULD FILL OUT YOU CAN'T ADD IT OR THEY'LL SEND THE APPLICATION BACK. >> FOR THE PARENT ANNOUNCEMENT THEY'VE SAID EXCEPT FOR BLANK EVALUATION, AND WE'RE ABLE TO ASK FOR THINGS SPECIFICALLY. ANY FOA YOU WRITE, WHATEVER IS IN THE FOA GOES. >> IS THERE ANY INFORMATION ABOUT OUR ASKING THE PERSON WRITING THE GRANT HOW MANY OF THEIR STUDENTS HAVE FIRST-AUTHORED PUBLICATION BY THE TIME THEY GRADUATE BUZ THAT VARIES TREMENDOUSLY EVEN AT INSTITUTIONS THAT ARE SUPPOSEDLY THE BEST. >> THE CURRENT PLACE IS THERE'S A REQUIRED TRAINING TABLE WHERE PUBLICATIONS ARE PART OF THE TABLE. IT'S AN EXTENSIVE TABLE BUT THAT'S ONE WE'RE KEEPING BECAUSE THAT'S ONE WHERE THEY CAN SEE. THE BIG QUESTION AT NIH IS HOW DO YOU SORT IT? DO YOU SORT IT BY TRAINEE OR MENTOR AND SEE HOW MANY AUTHORSHIPS DOES THAT PARTICULAR MENTOR HAVE. THERE'S SOME QUESTION AROUND THAT. FOR US WE'RE INTERESTED IN THE FOCUS ON THE TRAINING. WE'RE WORK THE OFFICE OF EXTRAMURAL RESEARCH ON OUTCOMES. IN THE PAST IF A TRAINEE WAS LEFT OFF IT'S REALLY HARD TO TRACK THAT BUT NOW WE'RE GOING TO HAVE IT SUCH THAT YOU CAN'T LEAVE ANYBODY POCH -- OFF. IT WILL BE THERE FOR THE REVIEWERS TO EVALUATE. >> I'M A CO-DIRECTOR FOR ONE OF THE P32s AND IT'S BEEN HARD AND IT'S A TREMENDOUS AMOUNT OF WORK TO ADDRESS THE POINTS. WE'RE STILL WORK TO ADDRESS IT AND WE CAN'T CHANGE THE HISTORICAL PAST BUT WE CAN DEMONSTRATE GOOD-FAITH EFFORTS TO INTRODUCE SOME OF THESE CHANGES. IT'S SOMETHING I HOPE THERE'S ACCOMMODATION FOR THAT. WE ARE PUTTING TABLES TOGETHER AND SUBMITTED A RENEWABLE AND IT'S GOOD TO SEE THAT BUT HARD TO CHANGE. >> I THINK HONESTY IS APPRECIATED NOT COVERING UP THE PAST. THE BIG QUESTION IS WHAT DO YOU PLAN TO DO GOING FORWARD? IT NEEDS TO BE THOUGHTFUL AND SOMETHING YOU THOUGHT HARD ABOUT. THAT WILL BE WELL RECEIVED. YOU CAN'T CONTINUE TO PENALIZE PEOPLE FOR THE PAST. HONESTY IS APPRECIATED IN THE PANEL. >> LISA AND MIKE AND OLIVIA. >> I WAS EXCITED TO SEE YOU'RE ASKING SPECIFIC INFORMATION IN HOW TO EVALUATE OUTCOMES AND DISSEMINATION PLAN AND WONDERING IF YOU COULD SAY MORE WHAT YOUR GOALS ARE IN TERMS OF DISEM NAGE NAGE -- DISSEMINATION AND EVALUATION. >> I THINK THERE'S LOTS OF LEVELS. THE FIRST LEVEL IS IF YOU'RE FORCING ENCOURAGING EVALUATION IS THERE ARE ITERATIVE IMPROVEMENTS. IF YOU ASK TRAINEES ON EXIT INTERVIEWS THEIR EXPERIENCE AND DID THEY HAVE THE SKILLS THEY NEEDED. ARE THEY REACHING OUT TO LUMS TO SEE HOW THEY FARED AND HAVE A DIRECT IMPACT ON THE PROGRAM. THAT'S ONE LEVEL AND LISTENING TO STUDENTS. I THINK WE'RE ALSO INTERESTED IN FOR PEOPLE WHO GET REALLY EXCITED ABOUT IT, THEY COULD POTENTIALLY TEST THEIR NEW INNOVATION. THEY HAVE VERY EXCITING CURRICULUM THEY THINK IS WORTH GETTING OUT THERE. THEN ENCOURAGING THAT VENUE AS WELL. WE HAVE A PROGRAM DIRECTOR'S MEETING WHERE THERE IS AN INFORMAL PLACE TO DO THAT AND THOSE WHO REALLY GET EXCITE ABOUT IT TO DO IT AND TAKE A RESEARCH ON INTERVENTIONS APPROACH MORE QUANTITATIVELY AND THERE'S A WHOLE CONTINUUM WE'D ENCOURAGE OUR PROGRAM FOLKS TO BE INVOLVED IN. THE BEAR MINIMUM IS TO SELF-ASSESS. IT'S INTERESTING HOW LITTLE THAT IS DONE UNLIKE JUST SAYING WHERE PEOPLE ENDED UP. >> MAYBE ONE THING THAT CAME OUT OF THE DISCUSSION WITH THE T.W.D. MEETING THE COMMUNITY BY AND LARGE FINDS THE IDEA OF EVALUATING THEIR PROGRAMS PRETTY SCARY BUT NOT SURE HOW TO DO IT. IN THIS SCENARIO WHERE I THINK THOSE DEANS OF VARIOUS KINDS AND IF THEY'RE NOT EVALUATING THEIR PROGRAM ATTIC OUTCOMES IT'S -- PROGRAMMATIC OUT.com AND -- OUTCOMES AND YOU KNOW THOSE BODIES ARE INCREASINGLY EXPECTING TO SEE EVALUATIONS AND OUTCOMES AND ANALYSES. I'M NOT SURE HOW INSTITUTIONS WILL GET THROUGH THOSE IN THE FUTURE IF THEY DON'T HAVE INFRASTRUCTURE FOR DOING THIS AND IF YOU DON'T HAVE THIS YOU MAY BE UNTROUBLE. >> ONLY THE DEVELOPMENT OFFICE KNOWS. [OFF MIC] [OFF MIC] >> DON'T GET PE WRONG. WE'RE KEEPING -- DON'T GET ME WRONG. WE'RE KEEPING MANY TABLES. IT'S ONE OF SEVEN OR SOMETHING AND ONE IN PARTICULAR TO GIVE YOU -- YOU HAD TO LOOK UP THE INSTITUTION OF ORIGIN OF EVERY APPLICANT NOT METRICULANT AND THEN YOU HAVE TO CALCULATE AND GIVE THE INSTITUTIONS OF THE ONES WHO YOU ACCEPTED INTO THE PROGRAM. SOMEONE CAME TO ME ONE DAY AND GAVE ME A 26 PAGE TABLE SIX. WHAT YOU WANT TO KNOW IS HOW BROAD OF A REACH ARE YOUR APPLICANTS. ARE THEY ONLY COMING FROM A FEW INSTITUTIONS. WE CAN ASK THEM IN THE TEXT AND IN A WAY AND ASK IN A WAY THAT DOESN'T RETIRE THIS HUGE ADMINISTRATIVE BURDEN. GETTING SOME OF THE SAME IMPORTANT INFORMATION. THEY DON'T JUST TRUST THE INTERPRETATION OF THE DATA IN THE TEXT. >> WHEN WE'RE THINKING ABOUT COMMITMENT TO DIVERSITY AND INCLUSION, THE APPLICANT POOL AND ACCEPTANCE POOL AND TRAINING OF MENTORS AND HOW INSTITUTIONS RESPOND TO HARASSMENT. SO I GUESS I WAS WONDERING HOW YOU THINK IN EVALUATING THAT ASPECT ESPECIALLY BECAUSE THERE'S STRONG SELECTIVE PRESSURE ON PROGRAMS TO NOT REPORT THE THINGS THAT LURK BEHIND THE SCENES. I'M WONDERING HOW THAT GOES INTO YOUR THINKING WHEN YOU'RE TALKING ABOUT DIVERSITY AND INCLUSION. >> WE'RE LISTENING BUT THE PLACE WHERE IT EXISTS NOW IS IN THE INSTITUTIONAL COMMITMENT LETTER. THEY HAVE TO DESCRIBE THEIR CURRENT PRACTICES FOR DEAL WITH HARASSMENT AND DISCRIMINATORY EVENTS ON CAMPUS. THAT'S RETIRED AND HAS TO BE SIGNED BY A PROVOST OR HIGH-LEVEL OFFICIAL. WE ARE NOT ASKING FOR IT EXCEPT IN THE RESEARCH ENVIRONMENTS. WE'RE NOT SPECIFICALLY SAYING WHAT THEY'RE DOING TO ADDRESS HARASSMENT BUT IT FALLS UNDER THE IDEA OF INCLUSION. WE'RE LETTING INCLUSION BE IN THE BROAD SENSE OF THE WORD. >> SOMETHING RELATED TO THAT IS IN MENTOR ASSESSMENT, MENTOR TRAINING AND THERE NEEDS TO BE A PLAN FOR HOW THE PROGRAM WILL DEAL WITH MENTORS AND REMOVE THEM IF NECESSARY. IF PETER WANTS TO ADDRES THAT IT GIVES LICENSE TO PROGRAMS TO HAVE A MORE STRONG IMPACT ON WHO IS MENTORING. >> THINGS UNRELATED TO TITLE 9 ISSUES. I THINK A MESSAGE THAT CAN COME THROUGH FROM GM AND I FEEL STRONGLY ABOUT IS THAT MANY FACULTY FEEL IT'S THE RIGHT TO TRAIN STUDENTS AND IT'S NOT SIMPLY A PRIVILEGE TO DO THAT. I THINK AS WE CAN EMPOWER PROGRAM DIRECTORS TO FEEL AS THOUGH YOU DON'T NEED A TITLE NINE FINDING TO THROW SOMEBODY OUT OF YOUR PROGRAM. IT DIDN'T HAVE TO BE THAT LEVEL. IF SOMEONE'S NOT SUPPORTING THEIR STUDENTS AND CONTRIBUTING TO THEIR ENVIRONMENT YOU SHOULD BE FULLY EMPOWERED. THAT'S DIFFICULT AND REQUIRES LEADER FROM THE SCHOOL OR UNIVERSITY LEVEL BECAUSE THEY'RE OFTEN PEERS AND COLLEAGUES. THAT'S SOMETHING TO CONSIDER. >> I'D BE INTERESTED TO HEAR AND WE HAVE LANGUAGE NOW ABOUT REMOVING INDIVIDUALS THAT SHOW POOR MENTORSHIP QUALITIES AND WHETHER IT'S STRONG ENOUGH AND DIRECTED ENOUGH. WE TRIED TO PUT COMPONENTS OF THAT THERE TO SPEAK TO YOUR POINT WHICH IT IS A PRIVILEGE, NOT A RIGHT AND THAT INCLUDES NOT NECESARILY BEING PUT ON JUST BECAUSE YOU HAVE THE LARGEST RESEARCH GRANTS IN THE DEPARTMENT THAT YOU ACTUALLY HAVE TO HAVE THE BANDWIDTH AND COMMITMENT TO TRAINING AND MENTORING. >> I THINK IT WILL TAKE A LITTLE BIT OF TIME AS A RESULT OF THE EVALUATIONS AND ASKED FOR DE IDENTIFIED RANKINGS. >> OR ASKING THE SELECTION PROCESS. >> WHATEVER YOU CAN ENSURE IT'S HAPPENING. A PLAN IS A PLAN. >> AT SOME LEVELS I THINK THE COMMITTEES WANT TO HEAR YOU SAY YOU REMOVED ONE OR MORE FACULTY MEMBERS OVER THE PREVIOUS FIVE YEARS NOT IDENTIFYING THEM BUT -- YOU THINK THAT MIGHT BE SOMETHING THAT COMMITTEE WOULD SAY IS A POSITIVE. IF YOU HAD TO REMOVE 10, MAYBE THEY THINK THERE'S A PROBLEM. >> IT'S GOING TAKE A CULTURED CHANGE AT THE REVIEW LEVEL AND THE SRO AS WILL BE AN IMPORTANT PART OF THIS AND THE REVIEWERS HAVE TO LOOK AT THIS AND YOU MAY HAVE PEOPLE THAT ARE ENTHUSIASTIC AND PASSIONATE AND THEY'RE GREAT MENTORS AND MAY HAVE THE RESOURCES BUT IF THEY'RE NOT GOOD ON PAPER THE REVIEWERS KNOCK IT. >> WE'RE LUCKY THESE ARE BEING REVIEWED IN THE NIGMS OFFICE OF SCIENTIFIC REVIEW AND YOU CAN HERE A SHIFT IN CONVERSATIONS. IT DOESN'T HAVE TO BE NIH FUNDING PARTICULARLY IN THE COMPU COMPUTATIVE FIELDS SO LONG AS THERE'S RESOURCE TO ENSURE STUDENTS ARE TRAINED WELL BECAUSE IT HAS TO BE AN EXCELLENT TRAINING ENVIRONMENT. IT DIDN'T HAVE TO BE OFF THE CHART. >> DO I HAVE A MOTION TO APPROVE THE CONCEPT? SECOND? ALL IN FAVOR? ANY MOVED? >> WE'LL MOVE TO HALUK WHO WILL TELL YOU ABOUT THE NEW PROPOSED PROGRAM WHICH IS DERIVATIVE OF PREVIOUS PROGRAMS TO ISSUE R25 GRANTS TO SUPPORT THE CREATION OF TRAINING MODULES TO ENHANCE REPRODUCIBILITY AS WELL AS RESPONSIBLE CONDUCT OF RESEARCH FOR BIOMEDICAL DATA SCIENCE RESEARCH. IT'S EN PART IN SUPPORT OF THE NIH STRATEGIC PLAN FOR SCIENCE WHICH SUSAN IS MANAGING THE EXECUTION OF. >> HELLO, EVERYBODY. I'M PRESENTING THE NEW TRAINING MODULE DEVELOPMENT. THIS WILL SUPPORT THE SCIENTIFIC RIGOR. AND RESEARCH. NIH AND NIGMS IS SUPPORTING AND NIGMS IN THE PAST ISSUED TWO FYIs AND THE TRAINING MODULES ARE AVAILABLE. ALSO NIH HAS A LIST AND THERE'S CALL TO IMPROVE THE TRAINING WORKFORCE DEVELOPMENT IN THE DATA SCIENCE AREA. THIS TRAINING MODULE PROVIDES MATERIAL FOR STRATEGIES. THE BIOMEDICAL DATA SCIENCE AND TRAINS THE NEXT GENERATION OF SCIENTISTS IN THE IMPACT OF RESEARCH. THEN WE TALK ABOUT MODULES. THESE ARE SHORT TRAINING MODULES AND THEY CAN BE STAND ALONE OR COMBINE FOR COURSES FOR SEMESTER LONG OR YEAR LONG COURSES. AND THE RCR TRAINING PROGRAMS AND THESE MODULES WILL GO TO THESE IN GENERAL AS WELL. THOSE MODULES ARE EXPECTED TO BE AVAILABLE TO EVERYBODY AT NO COST. SOME SUBJECTS WE'RE THINKING ABOUT IS PRINCIPLES OF DATA SCIENCE LIKE HOW WE BETTER MANAGE THE DATA FROM THE COLLECTION STAGE OF THE PROCESSING STAGE AND ALSO HOW TO INTERPRET THE DATA AND FOR RCR AND HOW TO PREPARE THE CONSENT FORMS. AND HOW WE DEAL WITH THE DATA. AND HOW WE ARE GOING TO GIVE ACCESS TO DATA WHO HAS THE DATA AND SOLVE THOSE IN PLACE. ERROR THE RNR HOW WE COLLECT THE METADATA AND WHAT THE PROPER VERSIONS FOR SOFTWARE DEVELOPMENT AND THIS IS BASED ON PAST EFFORTS AND IF WORKING PROPERLY WE'LL ASK FOR SHORT MODULES AVAILABLE TO EVERYONE AT NO COST AND PROVIDE LINKS AT THE WEBSITE AND THE FIRST TWO YEARS ARE FOR DEVELOPMENT IN TERMS OF COST ASKING FOR THE OPERATION FOR THREE YEARS AND EXPECT TO MAKE FOUR TO SIX AWARDS. IN THE PAST WE EXPECT TO CONTINUE AND EXPECT THEM TO PUBLISH AND TARGETING THE 2021 COUNCIL AND STAFF AFTER THAT. I'D LIKE TO MENTION NIGMS IS PLAN TO ISSUE AN FOA IN TERMS OF MODULE DEVELOPMENT AND WE'LL CHANGE THE SUBJECT OF THE MODULES AND WILL LOOK AT THE DATA SCIENCE. WITH THAT I'D LIKE TO TAKE YOUR QUESTIONS. >> QUESTIONS OR COMMENTS. >> HOW ARE YOU IMAGINING THAT PEOPLE WILL SHARE THESE MODULES THROUGH WEBSITES OR SOMETHING? AND SOME SITES MAKE THEM AVAILABLE FOR FREE. THE MODULES STAY IN THE INSTITUTIONS. >> SO HOW DO YOU MEASURE THE IMPACT ANALYSIS OF THIS INVESTMENT? SITES CAN KEEP A COUNTER OF HOW MANY PEOPLE ACCESS MODULES, LISTEN TO THEM AND DOWNLOAD THEM. AND COME TO THE LARGER SCALE TRAINING PROGRAMS AND NOT THAT EASY TO DO BUT MAYBE AS PART OF THE PLAN AND SOME ARE IN TERMS OF THE USE OF THE MODULES. >> WE SAW INSTITUTIONS INCORPORATING THESE INTO THEIR CURRICULUM. >> AND IT'S GREAT TO HAVE INVESTIGATORS. >> PEOPLE ARE INVOLVED IN THE DATA SCIENCE THEY'RE MOSTLY FROM DATA SCIENCES. SO THEY ARE NOT FAMILIAR WITH THE BIOMEDICAL RESEARCH. GIVES A GOOD OPPORTUNITY TO LEARN. >> DO I HAVE A MOTION IT APPROVE. ALL IN FAVOR? ANY OPPOSED? >> OKAY. SO THANK YOU VERY MUCH HALUK. THAT CONCLUDES THE PART WE HAD FOR YOU IN THIS OPEN SESSION BUT WE NORMALLY AT THIS STAGE INVITE MEMBERS OF THE PUBLIC AND SOCIETIES TO COME FORWARD AND SAY ANYTHING FOR A MINUTE OR TWO. I DIDN'T GET CARDS INDICATING AN INTEREST IN DOING THAT BUT FASA HAS APPARENTLY NOTHING TO SAY WHICH IS IMPRESSIVE. I THOUGHT WAMC IS HERE AS WELL. NOTHING FROM THEM? NO? OKAY. IN THAT CASE, WE WILL ENCOURAGE YOU NEXT TIME TO THINK OF SOME EXCITING THINGS TO TELL US ABOUT AND WE'LL BREAK FOR LUNCH AND AFTER THAT THIS IS THE END OF THE OPEN SESSION.